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Abstract
Solid-phase extraction techniques were evaluated for the extraction of P-agomsts from 
biological matrices prior to determination by radioimmunoassay
Clenbuterol was extracted from aqueous liver homogenates using a 
combmation of on-column liquid/liquid partitioning coupled to a silica sohd-phase 
extraction step following initial enzymatic digestion of the liver sample The procedure 
was validated at fortification levels of 0 2 and 0 4 ppb clenbuterol Recovery of 
clenbuterol was greater than 60% at both concentrations
Four P-agomsts were extracted from bovine unne and liver samples 
using mixed-mode sohd-phase extraction columns The procedure was validated for 
clenbuterol, mabuterol, salbutamol and terbutalme at levels of 2 and 5 ppb The mean 
recovery for the P-agomsts from liver and unne was greater than 75% and 85%, 
respectively The limit of detection was 0 13 ng/ml and 0 46 ng/g of clenbuterol in unne 
and liver, respectively
Clenbuterol and salbutamol were extracted from bovine liver samples 
using a mixed-mode matnx sohd-phase dispersion/ion exchange procedure Four types 
of sorbent were mvestigated m order to determine which sorbent combined most 
effectively with the ion exchange matenal in retaining the P-agomsts Recovery of 
clenbuterol and salbutamol from liver samples fortified at 50 ppb was greater than 80%, 
the resulting extracts were insufficiently punfied to allow for determination of P- 
agomsts at low or sub-ppb levels An enzymatic hydrolysis step was required for the 
determination of conjugated residues of salbutamol m incurred liver samples
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CHAPTER 1 
INTRODUCTION
1
1.1 3-AGONISTS
Noradrenaline is an adrenergic neurotransmitter which is synthesised and stored in 
peripheral nerve endings The molecule stimulates adrenergic receptors within the 
immediate vicinity and does not normally enter the plasma in sufficient quantities to act as 
a circulating hormone Adrenaline is a circulating hormone of the adrenal medulla and 
influences physiological events at adrenergic receptors throughout the body 
The adrenergic receptors have been divided into both a- and P- subtypes m order to 
describe the ability of adrenergic agonists to cause contraction (a- effect) or relaxation (P* 
effect) of smooth muscle The response of a tissue to a particular agonist depends on the 
presence and proportion of a- and p- receptors and the ability of the agonist to interact 
with the receptors p-Receptors can be subdivided further into pi and P2 receptors The 
p-receptors of the heart and intestinal smooth muscle are classified as pi type, while the 
receptors of the bronchial, vascular, and utenne smooth muscle are classified as p2 
receptors [1 ]
Synthetically produced P-agomsts are close analogues of adrenaline and noradrenaline, 
and consequently have the ability to influence various metabolic and physiological 
processes The structures of seven p-agomsts, along with adrenaline and noradrenaline, 
are shown in Figure 1 1 Synthetic compounds which selectively stimulate pi or p2 
activity have been used in the treatment of cardiac failure and asthma, respectively The 
selective nature of these compounds results in reduced side effects particularly in the 
treatment of bronchial problems where stimulation of cardiac functions is undesirable
Figure 1 1 Structures of seven ß-agomsts, adrenaline and noradrenaline
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1.2 THERAPEUTIC USE OF |3-AGONISTS IN HUMAN AND
VETERINARY MEDICINE
P-Agomsts are used to treat chronic obstructive airway diseases in both humans and 
animals Another use has been m pregnant mammals for tocolysis These compounds 
achieve the desired effect through their selective stimulation of the p2 receptors on 
bronchial and utenne muscles Although most of the p-agomsts shown in Figure 1 1 are 
used in human medicine, only clenbuterol is used in veterinary treatment at a 
recommended dosage of 0 8 |ig/Kg bodyweight twice daily for a maximum period of ten 
days [2] The selectivity of P-agomsts for the p-receptors has been increased significantly 
based on knowledge that stimulation of a P-receptor is achieved by molecules containing 
an aromatic group with an ethanolic group at the a-position and a secondary amine with 
bulky substituents (Figure 1 2)
1.3 (RE)-PARTITIONING EFFECTS OF (3-AGONISTS IN 
MEAT PRODUCTION
The first reported effects of treatment with p-agomsts to alter fat and muscle deposition in 
steers [3], lambs [4] and broilers [5] were in 1984, and all results originated from the 
American Cyanamid Co in Princeton, New Jersey The effects of a variety of p-agomsts 
on the growth performance and carcass quality of sheep, cattle, pigs and poultry have been
Figure 1 2 ’Template" for p-agomst activity
4
reviewed extensively elsewhere [6,7] Both reviews have concluded that p-agomsts can 
be used to effect nutrient repartitiomng so that the composition of growth is altered to give 
less fat and more lean in the carcass of meat animals
t
These compounds are orally active and are effective at a concentration of around 0 25 ppm 
to 4 ppm m feed dependmg on the species The repartitiomng effect is much greater in 
ruminants than m pigs or poultry, but nevertheless is commercially important for all 
species On the negative side, P-agomsts have also been found to increase the meat 
toughness in ruminants and poultry Table 1 I demonstrates the effects of P-agomsts on 
lean and fat values in cattle, sheep, poultry and pigs [7]
Table 1 1 The effects of p-agomsts on the lean and fat values of meat producmg animals
Animal Increase in trimmed lean 
(%)
Reduction in dissectable fat 
(%)
Cattle 10 30
Sheep 18 41
Poultry 6 17
Pigs 5-10 27
The level of p-agomsts required to promote a repartitiomng effect ranges from 0 25 ppm 
to 4 ppm in feed [7], while the therapeutic level for clenbuterol in cattle is 0 8 Jig/Kg 
bodyweight [2] The therapeutic level differs, therefore, from the repartitiomng level by 
an order of magnitude, for example, 0 32 ppm clenbuterol m sheepfeed, given an average 
weight of sheep of 40 Kg and an average daily consumption of 1 Kg feed, represents 8 
jag/Kg bodyweight, which is 10 times the therapeutic level
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1.4 (3-AGONIST RESIDUES IN TISSUES OF TREATED 
ANIMALS
The use of compounds with hormonal or thyreostatic action was prohibited within the EU 
m 1986, except under veterinary prescription [8] Nevertheless, several cases of food 
poisoning were reported m Spam when bovine liver containing high levels of clenbuterol 
was consumed [9] The results of two pharmacokinetic studies on residues of clenbuterol 
present in the liver, kidney and unne of sheep and veal calves after treatment at levels in 
excess of the recommended therapeutic dose are shown m Table 1 2 The levels of 
clenbuterol determined in kidney and liver indicate the potential danger of eating tissues 
from animals which have been treated illegally with clenbuterol Both of these studies 
have shown that unne (and other biological fluids such as plasma and bile) contain 
appreciable levels of clenbuterol during the treatment period, but once a withdrawal period 
is initiated, the levels of clenbuterol rapidly dimmish, and residues only remain detectable 
in organs and tissues after a three day withdrawal period Urine, and other biological 
fluids, are useful therefore as analytical samples where "on-farm" sampling is possible and 
where no withdrawal period has been observed The bovine eye has also been shown to 
accumulate residues of clenbuterol at levels greater than those found in the liver [1 1 ,12], 
but no pharmacokinetic data are available which cover the accumulation of other p- 
agomsts in this tissue Salbutamol also has been shown to accumulate in the liver of 
treated animals [13], which would indicate that this organ is a useful matrix for residue 
analyses The high accumulation of clenbuterol in the eye is offset by the small sample 
size available ( 1-2 g), which may not provide enough sample for both screening and 
confirmatory work
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Table 1 2 Concentration of clenbuterol in liver, kidney and unne of ovine and bovine 
species treated above the recommended therapeutic dose and with no withdrawal period
Animal Organ Therapeutic dose (x times) Clenbuterol (ng/g) Ref
Lambs Liver 1 20 2 [10]
10 162 0
25 302 4
Unne 1 36
10 1187
25 1412
Kidney 1 164
10 83 9
25 267 2
Calves Liver 6 25 39 0 [1 1 ]
Kidney 6 25 33 0
Unne 6 25 449
1.5 CONCLUSION
P-Agomsts have both a therapeutic and repartitiomng effect m meat producing animals 
depending on the concentration used Although the use of these compounds as (re)- 
partitioning agents in the rearing of animals has been banned within the EU, their growth 
promoting properties ensure that their illegal usage must be continuously momtored 
Pharmacokinetic studies have revealed that residues of P-agomsts accumulate in both the 
liver and eyes of meat producing animals, and that these residues persist when the 
treatment programme has ceased These tissues are therefore of major mterest in the 
detection of p-agomsts residues, particularly the liver, due to its size and relative 
accessibility at time of slaughter
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CHAPTER 2 
REVIEW OF CURRENT METHODS FOR THE 
DETERMINATION (3-AGONISTS IN 
BIOLOGICAL MATRICES
10
2.1 INTRODUCTION
This review focuses on the main stages of a residue detection method, namely,
1 sample pretreatment,
2 clean-up techniques,
3 chromatographic separations (optional),
4 determination
Each of these stages will be discussed with specific reference to the determination of p- 
agomst residues m biological fluids and tissues
2.2 SAMPLE PRETREATMENT
Sample pretreatment involves the techniques used with biological matrices in order to 
present them m a suitable format for residue extraction The techniques used in sample 
pretreatment depend on the matrix under consideration, liquids requiring generally less 
pretreatment than tissues The tissues are normally first homogemsed, and after this step 
the tissues may be enzymatically digested or somcated in order to liberate residue from the 
sample matrix Enzymatic digestion techniques were used initially by Degroodt et al [1] 
m the analysis of clenbuterol by high performance liquid chromatography (HPLC) and 
high performance thin layer chromatography (HPTLC) In their method a 5 g portion of 
tissue was incubated with 5 mg subtihsin A and 10 ml 0 2 mol/1 Tns buffer, pH 8, 
containing 0 1 mol/1 CaCl2 in a closed 30 ml centrifuge tube for one hour This sample 
pretreatment technique has since been used in the preparation of clenbuterol extracts prior 
to enzyme immunoassay (EIA) [2,3,4] and gas chromatography coupled with mass 
spectrometry (GC-MS) [5]
A sample pretreatment technique using subtihsin A has also been described by Leyssens et 
al [6] for the analysis of seven P-agomsts m liver, the sample extracts being finally
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analysed by GC-MS Sample pretreatment involving the somcation of homogemsed tissue 
samples in an acidic environment, in order to precipitate proteins, has been described for 
the analysis of clenbuterol and salbutamol with determination by HPTLC [7], HPLC with 
fluorescence detection [8], HPLC with ultra violet (UV) detection [1,9] and EIA [10] 
Other sample pretreatment procedures merely involve homogemsation of the tissue in 
perchloric acid [11], Sorensen buffer [12] or potassium carbonate [13] pnor to further 
sample cleanup Urine samples do not require an extensive pretreatment step, as 
centrifugation of the sample [14] or filtration [15,16] generally results in samples suitable 
for the cleanup procedure
2 2 1 DECONJUGATION OF p-AGONIST RESIDUES PRIOR TO 
RESIDUE EXTRACTION AND CLEAN-UP
Many drugs and metabolites are present in unne and tissues as conjugates, such as 
glucuromdes or sulphates, which are very polar and essentially not directly extractable into 
organic solvents Generally it is necessary to hydrolyse these conjugates so as to release 
the parent molecule for extraction and determination This is usually achieved chemically 
with hydrochloric acid or sodium hydroxide, or enzymatically with enzymes such as p- 
glucuronidase, sulphatase or sue d'Helix pomatia (SHP), which contains both p- 
glucuronidase and sulphatase enzymes
Haasnoot et al [15] showed that clenbuterol is mainly present in unne as the free 
molecule, and that a deconjugation step involving SHP resulted m lower levels of 
clenbuterol being determined, probably due to the degradation of clenbuterol dunng the 
two hour incubation at 37°C Both glucuromde and sulphate conjugates of salbutamol 
have been determined m the unne [17] and tissues [18] of treated calves The use of a 
mixed enzyme preparation of glucuronidase and sulphatase, such as SHP, is required,
1 2
therefore, for deconjugation of salbutamol The conditions used for hydrolysis with SHP 
vary from 2 hours at 37°C [19] to 20 hours at 50°C [18], but most methods use an 
overnight deconjugation step at 37°C [17,20,21] Metaproterenol conjugates have been 
chemically hydrolysed m human plasma samples by incubation for 90 minutes at 65°C in 
an acidic environment [22] Following deconjugation of the P-agomsts, the various 
sample extraction and clean-up techniques discussed below can be applied
2.3 SAMPLE EXTRACTION AND CLEAN-UP 
TECHNIQUES
Sample extraction and clean-up techniques can be divided into solvent extraction, 
liquid/liquid partitioning, solid-phase extraction and immunoaffmity chromatography
2 3 1 SOLVENT EXTRACTION
Extraction of the aniline type P-agonists (clenbuterol and mabuterol), which lack 
phenolic groups on the benzene ring, has been undertaken using polar solvents under 
alkaline pH conditions Salbutamol, terbutaline and other P-agomsts, which have aromatic 
phenolic groups, are not efficiently extracted with this procedure due to their high polarity 
Tert-butylmethylether has been used to extract clenbuterol from animal feed, tissues and 
unne [23], biological fluids [24] and faeces [25] Extraction of clenbuterol from unne [2] 
and tissues [5,11] using diethyl ether has been reported Mabuterol, cimaterol and 
clenbuterol were extracted from unne samples with diethyl ether pnor to determination by 
a radioreceptor assay [26] Mixtures of organic solvents, such as diethyl ether «-butanol 
(9 1), have been used to extract clenbuterol from unne [27,28] and mabuterol from 
plasma samples [29] The increased polanty of the solvent resulted in recovenes of
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greater than 90% for both compounds Some extractions involve an initial ’'washing” of 
the samples at an acidic pH, where clenbuterol is charged and will not leave the aqueous 
phase The aim is to remove interferences, such as lipids, in the first extraction, after 
which the pH is adjusted to alkaline conditions and clenbuterol is extracted Petroleum 
ether [30,10] and tert-butylmethylether [27] have both been used as "washing solvents" 
After the extraction, the solvent is evaporated and the sample extract is reconstituted in an 
appropriate solvent prior to analysis by thm layer chromatography (TLC) [31], HPLC with 
electrochemical detection [29,30] or by immunoassay [24,25] A back extraction step 
involving the addition of hydrochloric acid to the organic phase is often used to effect 
clean-up and preconcentration of clenbuterol into a small volume pnor to analysis 
[1,11,32] or further clean-up Further clean-up may mvolve washing the acidic extract 
with ethyl acetate hexane (2 1) [12] or hexane and tert-butylmethylether [33] pnor to the 
re-extraction of clenbuterol into an organic solvent under alkaline conditions
2 3 2 ION-PAIR EXTRACTIONS AND SALTING OUT 
TECHNIQUES
A useful approach to dealing with a highly polar drug such as salbutamol or terbutaline, is 
to convert it into a neutral ion-associating complex by addition of an excess of suitable 
ions of opposite charge and extract the analyte into an organic solvent Di(2- 
ethylhexyl)phosphate (DEHP) has been used to extract salbutamol from plasma and serum 
as an lon-pair complex into chloroform [34,35] and ethyl acetate [36] The addition of 
hydrochloric acid to all three organic extracts was used to back-extract salbutamol into a 
small volume pnor to analysis by HPLC or further clean-up [36]
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In some cases, a salting out procedure (addition of an excess of salt to the sample before 
extraction) can shift the partition equilibrium in favour of the extraction Leyssens et al 
[6] used a mixture of tert-butanol/ethyl acetate to extract seven p-agomsts, including 
clenbuterol and salbutamol, from a liver digest saturated with sodium chlonde, prior to 
determination by GC-MS Salbutamol has also been extracted from human plasma 
saturated with sodium chlonde (at pH 10 6) into ethyl acetate, with determination by GC- 
MS [37]
2 3 3 ON-COLUMN LIQUID/LIQUID EXTRACTION
Columns containing diatomaceous earth may be used to perform non-column" 
liquid/liquid extractions (LLE) The aqueous sample is usually poured into the column, 
and after an equilibration penod, the organic extracting solvent is added to the column and 
the eluate contaimng the analyte is collected This form of LLE benefits from havmg no 
shaking or centnfugation steps ‘ChemElut’ and ‘Extrelut’ columns are examples of two 
commercially available materials Sample clean-up using these columns in the extraction 
of P-agomsts involves adjusting the pH of the tissue homogenate or unne sample to pH 10 
or above pnor to its application to the column
Organic solvents such as hexane [1,38], dichloromethane [39], toluene dichloromethane 
[32], and tert-butylmethylether [40] have been used to extract clenbuterol from biological 
fluids and tissues Clenbuterol can be back-extracted from the resulting eluate with 
hydrochloric acid prior to analysis by HPLC [1,32,38] or further clean-up by solid-phase 
extraction [40] Alternatively, the eluate has been evaporated, followed by denvatisation 
of clenbuterol pnor to analysis by HPLC [39] Van Ginkel et al [20] used an ‘Extrelut’ 
column in a sample clean-up step for the analysis of five p-agomsts m biological tissues, 
fluids and animal feed, but poor recovenes of salbutamol from liver samples (40-50%)
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were reported This relatively low recovery was probably due to the on-column extraction 
step which used ethyl acetate as the extracting solvent, m this case the organic solvent did 
not have the required polarity to extract salbutamol from the hydrophilic environment
23 4 SOLID-PHASEEXTRACTION
Sohd-phase extraction (SPE) is frequently used in the extraction and clean-up of p- 
agonists from biological matrices As a fluid sample or sample extract is passed through a 
SPE column, the P-agorusts may be extracted from the sample onto the sorbent matenal 
m the column Using a suitable wash, interferences can be removed before the p-agomsts 
are recovered from the column with an elution solvent Four types of SPE, namely 
7 reversed-phase, normal phase, ion exchange and mixed-mode, have been applied to the 
extraction of P-agomsts
2 3 4 1 REVERSED-PHASE SOLID-PHASE EXTRACTION
These columns, which contain a non-polar stationary phase and depend on Van der Waals 
forces, have been used to retain p-agomsts from aqueous samples Sample clean-up 
steps involving Cl 8 reversed-phase SPE as the sole purification step in the analysis of 
clenbuterol m biological fluids have been reported, with determination by EIA [10,41,42] 
and GC-MS [43] Clenbuterol-contaimng liver samples have also been cleaned-up by C l8 
SPE following an initial somcation step in hydrochloric acid to precipitate proteinaceous 
matter [44,45]
C l8 SPE has been used to clean-up plasma and serum samples containing salbutamol 
prior to HPLC analysis with fluorescence [46] and electrochemical detection [47] These 
columns were used for the extraction of fenoterol, terbutaline and salbutamol from plasma 
samples with determination by GC-MS [48]
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Reversed-phase SPE columns have often been used in conjunction with other clean-up 
techniques Unne samples containing salbutamol have been cleaned-up usmg C l8 SPE 
prior to LLE with tert-butylmethylether [36] Similarly, both fenoterol and salbutamol 
were extracted into ethyl acetate usmg DEHP following preliminary clean-up of a serum 
sample with a C l8 cartridge [48] SPE clean-up steps have been reported also for the 
purification of clenbuterol-contaimng sample extracts following on-column LLE [40] and 
immunoaffmity column clean-up [49], or prior to immunoaffmity column clean-up in the 
analysis of liver samples for four p-agomsts (clenbuterol, salbutamol, terbutalme and 
mabuterol) with determination by EIA [50] The broad applicability of reversed-phase 
SPE for the clean-up of p-agomsts in various biological matrices is reflected in its use 
both as the unique, and also as a preliminary or final, clean-up step
2 3 4 2  NORMAL PHASE SOLID-PHASE EXTRACTION
Silica SPE columns, for which the major retention mechanism is based on hydrogen 
bonding and dipole-dipole mteraction, have been used to extract salbutamol [51] and 
terbutalme [52] from plasma samples, with determination by HPLC with fluorescence 
detection Fuerst et al [23] used a silica SPE column to clean-up tert-butylmethylether 
extracts of animal feed, tissues and unne contaimng clenbuterol, while Schmitz et al [53] 
also used a silica column to further purify tissue and unne extracts contaimng clenbuterol 
pnor to HPLC analysis
2 3 43  ION EXCHANGE SOLID-PHASE EXTRACTION
Ion exchange SPE columns, such as the 'XAD-2' vanety, have been used for the extraction 
of salbutamol from plasma [54] and unne [55] pnor to determination by mass 
spectrometry Lmdberg et al also used ion exchange columns for the clean-up of plasma
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samples containing terbutaline [56] and salbutamol [57] In general, these columns are 
used for the extraction of polar molecules such as salbutamol and terbutaline, while 
samples containing the less polar P-agomsts are usually cleaned up using reversed-phase 
SPE
2 3 4 4 MIXED-MODE SOLID-PHASE EXTRACTION
Mixed-mode SPE columns have been designed to provide two or more primary 
interactions for retention of P-agomsts from biological matrices These columns have 
both ion exchange and reversed-phase retention characteristics, and allow for the use of 
stronger washes The dual retentive character of these columns has been exploited 
successfully m the retention of both types of P-agomsts (aniline and phenolic types) from 
biological fluids and tissue extracts Both ‘BondElut Certify5 and ‘Clean Screen DAU’ 
mixed-mode SPE columns were used by Dumasia et al [58] m the analysis of clenbuterol 
in horse unne GC-tandem mass spectrometry was used to analyse for seven p-agomsts in 
bovine unne and liver extracts following a solid-phase extraction clean-up step using 
‘BondElut Certify' columns The liver samples, following enzymatic digestion, were 
cleaned-up by liquid/liquid and solid-phase extraction pnor to their application to the 
mixed-mode SPE columns Poor recovenes for salbutamol (<35%) and terbutaline (<25%) 
from unne and liver matnces were reported, but higher recovenes of clenbuterol (>50%) 
and mabuterol (>80%) were achieved from both matnces [6] Thirteen P-agomsts were 
determined at the low ng/ml level in bovine unne by GC-MS using 'Clean Screen DAU' 
mixed-mode SPE columns as the clean-up step The recovenes of salbutamol and 
terbutaline were 22% and 36%, respectively, while higher recovenes were achieved for 
clenbuterol (68%) and mabuterol (73%) [14] These columns were also used in a study of 
salbutamol metabolism in calves to purify both unne and tissue samples pnor to analysis
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by GC-MS [18] High recoveries of terbutaline (66%), clenbuterol (90%), and salbutamol 
(85%) were reported by Gambiola et el [59] for extraction from unne using ‘BondElut 
Certify’ columns with determination by EIA The suitability of mixed-mode sohd-phase 
extraction columns for the extraction ofboth types of P-agomsts from biological tissues 
and fluids requires the problem of low recovery for some of the more polar P-agomsts to 
be addressed However, the multi-residue extraction capability of these columns, coupled 
with the potential for extensive washing, indicates their potential in the development of 
multi-residue extraction techniques for P-agomsts
2 3 5 IMMUNOAFFINITY COLUMN CHROMATOGRAPHY
Immunoaffimty column chromatography (IAC) has been applied to the determination of 
residues of p-agomsts in biological extracts Antibodies raised against the p-agomsts, 
when immobilised on a solid support and packed into a precolumn, can be used for the 
selective extraction of the analytes Antibodies may be immobilized on solid supports in 
different ways, such as by means of physical adsorption, affinity adsorption or covalent 
binding to a stationary phase The p-agomsts may be eluted with either buffers or water- 
organic modifier mixtures Buffers change the lomc retention interactions, while organic 
modifiers denature the antibodies, with consequent release of the p-agomsts Unne 
samples containing clenbuterol have been cleaned up using IAC pnor to EIA analysis, 
recovery of clenbuterol was 80% and a limit of detection of 0 2 ng/ml was reported [16]
Liver, kidney and bile samples were analysed also using this column [3] and with a
\
commercially available IAC kit [4] which achieved a limit of detection of 0 5 ng/g 
Confirmatory analysis of clenbuterol in unne was earned out by GC-MS following a 
combined clean-up using IAC and SPE (C l8) techniques [49] Salbutamol also has been
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extracted from lyophihzed rat tissue [60] and liver samples [8] using an IAC purification 
step yielding recoveries of greater than 60%
Van Ginkel and co-workers [20] used polyvalent antibodies raised against clenbuterol and 
cimaterol in an IAC column to retain terbutahne, salbutamol, clenbuterol, mabuterol and 
cimaterol from tissues, unne and animal feed Two antibodies were used on the column, 
one retained P-agomsts with tert-butyl end groups, while the other retained cimaterol 
which has an iso-propyl end group The recovery for salbutamol from liver (40-50%) was 
less than the recovery for the other four (3-agonists (65 ± 8%) Schilt et al [71] used an 
IAC column containing anti-clenbuterol antibodies with relative cross-reactivities of 3 3%, 
3 3% and 2 8% for salbutamol, cimaterol and terbutaline, respectively The lowest 
detection levels for a positive identification of the analytes in feed, unne and liver samples 
were 10 ng/g, 3 ng/ml and 1 ng/g, respectively A combination of C l8 SPE and IAC has 
been used to extract four P-agomsts from unne with good recovenes for clenbuterol 
(75%) and salbutamol (65%) being achieved [50] From these examples it can be seen 
that IAC columns are suitable for extraction of both aniline and phenolic type P-agomsts 
from both biological fluid and tissue samples The selectivity of the retention mechanism, 
which relies on a highly specific antibody-antigen interaction, is an important feature of 
IAC, as opposed to other clean-up techniques such as solvent extraction or SPE, which are 
dependent on the affinity of the analyte(s) for one phase (solid or liquid) over another
2 0
2.4 CHROMATOGRAPHIC SEPARATION TECHNIQUES
2 4 1 HPLC SEPARATION SYSTEMS
The majority of HPLC separation techniques for p-agomsts utilise reversed-phase (RP) 
columns, with some use of normal phase columns Chicken liver [9] and rat brain [1 1 ] 
extracts containing clenbuterol have been separated from mterferences on reversed-phase 
C8 and C l8 columns, respectively, while plasma [61] and liver [8] samples containing 
salbutamol have been separated from interferences on reversed-phase columns prior to 
fluorescence detection
Ion pairing agents such as sodium heptane-sulfonic acid have been used in conjunction 
with RP columns for the analysis of clenbuterol in plasma [29] and pharmaceutical gels 
[62], and also for the analysis of salbutamol in serum [36] and plasma [63] samples 
HPLC mobile phases contaimng perchloric acid were used to separate salbutamol and 
terbutaline from plasma on a cation exchange column [52] The perchlorate ion, which 
forms an lon-pair with the p-agomsts, was also used in a column switching assay to 
separate salbutamol on a RP C2 column following its elution from a cation exchange 
preconcentration column [64]
A cyano (CN) loop column on a rheodyne valve was used to punfy plasma extracts 
contaimng salbutamol and fenoterol through a 1 ml water wash prior to separation on a 
C l8 analytical column with a perchlorate ion-containing mobile phase [65] Ion pair 
buffers containing sodium dodecyl sulphate and acetic acid (pH 3 5) have been used with 
acetomtnle as the organic modifier to separate clenbuterol and cimaterol in tissues, animal 
feed and faeces extracts [32] and clenbuterol in unne extracts [40] A liquid 
chromatographic column switching system for automated sample pretreatment and 
determination of clenbuterol in calf urine, consisting of an I AC precolumn, a C18 
preconcentration column and a RP analytical column, also used a sodium dodecyl sulphate
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(SDS)/acetic acid ion pair buffer m the elution step from the C l8 column and in the 
analytical separation step [15] Plasma samples containing terbutaline and salbutamol at 
overdose levels have been analysed recently with sample clean-up in a multidimensional 
column chromatographic method The sample was extracted, purified and concentrated on 
the C l8 precolumn prior to separation on the analytical column using a mobile phase 
containing 6 5 mM SDS [66]
Normal phase retention mechanisms have been used to separate salbutamol in rat tissue 
[60] and plasma extracts [34,51] with fluorescence detection Enantiomeric forms of 
salbutamol, following denvatisation [68], have been separated using chiral HPLC phases 
[67] and RP columns but it is important to note that most residue analysis schemes are 
concerned with the detection and quantification of p-agomsts in a biological sample and 
that the isomenc form of the analyte is of secondary importance
2 4 2 GAS CHROMATOGRAPHIC SEPARATION SYSTEMS
Due to the low volatility of P-agomsts and the possibility of adsorption of these polar 
compounds to the GC column, denvatisation is required pnor to any gas chromatographic 
step Silylatmg agents such as N-0-Bis(tnmethylsilyl)tnflouro-acetamide (BSTFA), N- 
methyl-N-Tnmethylsilyltnfluroacetamide (MSTFA), N-methyl-N(tert-butyldimethylsilyl) 
tnfluroacetamide (MTBSTFA), chloromethyldimethyl-chlorosilane (CMDMCS) and 
hexamethyldisilazane (HMDS) have been used to denvatise p-agomsts Other 
denvatisation agents, such as pentafluropropiomc anhydnde (PPA), phosgene, and boromc 
acids, have been applied successfully to GC separation of P-agomsts Table 2 1 lists the 
numerous denvatisation agents used for gas chromatographic separation of P-agomsts 
extracted from biological fluids and tissues The determination technique most commonly
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used in combination with gas chromatographic separation is mass spectrometry The 
fragmentation patterns of the various derivatives and their suitability to mass spectrometnc 
determinations are discussed in the section GC-MS determination (2 5 4 1)
Table 2 1 References to denvatisation agents used in the analysis of p-agomsts
by GC separation
Denvatisation agent Clenbuterol Salbutamol Multi-residue
BSTFA [9,49,69] [18,48,54] [14,20,53,70,71]
MSTFA [72] [6,58,59]
MTBSTFA [49]
CMDMCS [14,58]
HMDS [23,33] [73]
PPA [12]
Phosgene [13]
Boromc acid [5,27] [74]
2 4 3 THIN LAYER CHROMATOGRAPHIC SEPARATIONS
TLC and HPTLC methods for the separation of P-agomsts have all used 
chromatographic plates coated with silica gel 60 HPTLC has been used to separate 
clenbuterol and cimaterol from biological fluid and tissue extracts [32,44] and clenbuterol 
from unne and tissue extracts [1 ], while conventional TLC has been applied to clenbuterol 
analysis m urine [31,75] Extracts of liver [7] and unne [76] containing salbutamol have 
been separated using HPTLC techniques with quantification by densitometry
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2.5 DETERMINATION TECHNIQUES
The determination methods which can be applied to cleaned up extracts compnse the 
following
1 spectroscopic determination,
2 electrochemical determination,
3 immunoassay determination,
4 mass spectrometnc determination
2 5 1 SPECTROSCOPIC DETERMINATION 
2 5 11 APPLICATIONS OF HPTLC AND TLC
Absorption microdensitometry has been used to detect an mdoamline derivative of 
salbutamol in liver m  and unne [7,76] extracts at 650 nm with limits of detection of 2 
ng/ml and 1 ng/g in unne and liver, respectively The mdoamline dye was formed by the 
reaction of salbutamol with dimethyl-p-phenylenediamme to form 4-{[4- 
(dimethylammo)phenyl]imino}-2(hydroxy-methyl)2.5 cyclohe\adien-2one which was 
separated from interferences on a silica gel 60 TLC plate pnor to quantification (Figure 
2 1) Detection of clenbuterol and cimaterol residues in animal tissues and feed using 
absorption microdensitometry, after the TLC plates were sprayed with modified Ehrlichs 
reagent, have resulted m detection limits of 0 25 ng/g and 0 5 ng/g for cimaterol and 
clenbuterol, respectively, m liver extracts [44] and an even lower detection limit for 
clenbuterol in animal tissues and feed of 0 2 ng/g [32]
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SALBUTAMOL DIMETHYL-P-PHENYLENEDIAMINE
INDO ANILINE DYE
Figure 2 1 Reaction of salbutamol with dimethyl-p-phenylenediamme to form an 
mdoamline dye
2 5 12 APPLICATIONS OF HPLC WITH UV DETECTION
UV absorption spectrophometry has been applied to the quantification of p-agomsts both 
directly and after denvatisation Direct UV detection has been applied to clenbuterol 
determination m unne and liver extracts Although limits of detection of 0 5 ng/ml 
[15,40] have been achieved for unne analysis, the reported detection limits for muscle of 
33 ng/g [11] and for liver extracts of 2 ng/g [9], which are above the 0 5 ng/g maximum 
residue limit (MRL) for clenbuterol, lack the required sensitivity for residue analysis The 
poor sensitivity in conventional HPLC-UV determination of P-agonists has led to the 
development of denvatisation procedures which have decreased the limits of detection of 
clenbuterol by an order of magnitude A pre-HPLC denvatisation procedure, involving 
the reaction of clenbuterol with N,N-dimethylamline to form dimethylamlme-clenbuterol 
(Figure 2 2), has been used to detect clenbuterol in unne and vitreous humour extracts 
The detection limit of the initial method for clenbuterol m unne was 1 ng/ml [77] but this
limit was further decreased to 0 4 ng/ml in the analysis of both vitreous humour and unne 
extracts [39]
Figure 2 2 Clenbuterol-dimethylamlme derivative
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Post-column denvatisation reactions have been used also to analyse for both clenbuterol 
and cimaterol residues in biological fluids and tissue extracts The denvatisation reaction 
involves the couplmg of clenbuterol and cimaterol to N - 1 -napthylethylene diamine (NED) 
This reaction, which is based on the formation of a diazomum salt of clenbuterol and/or 
cimaterol under acidic conditions m the presence of rutnte ions pnor to the couplmg stage, 
is shown in Figure 2 3 The denvatised analytes result in very low limits of detection 
being achieved (Table 2 2)
Table 2 2 Limits of detection for clenbuterol and cimaterol m biological fluids and tissue 
extracts by UV detection following post column denvatisation with N-l- 
naphthylethylene diamine
Matnx ß~agonist Detection
wavelength
(nm)
Limit of 
detection
Tissues, feed, Clenbuterol 493 0 1 ng/ml (liquid)
faeces and biological 
fluids [32]
Cimaterol 537 0 2 ng/g (solid)
Liver [44] Clenbuterol 496 0 5 ng/g
Cimaterol 536 0 25 ng/g
Urine and tissues [1] Clenbuterol 500 0 25 ng/ml (liquid) 
0 5 ng/g (solid)
2 5 13 APPLICATIONS OF HPLC WITH FLUORESCENCE 
DETECTION
Spectrofluorometnc methods of analysis have been applied to the determination of many 
P-agomst residues in biological samples Fluorescence is one of several mechanisms by 
which a molecule returns to the ground state after it has been excited by absorption of 
radiation Fluorescence is expected from molecules which contain an aromatic nng, 
however, the presence of electron-withdrawing groups on the aromatic nng such as
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chlorine (clenbuterol) and flounne (mabuterol) decrease fluorescence capability 
dramatically This explains why most HPLC-fluorescence detection systems have been 
applied to salbutamol, which contains no electron-withdrawing groups 
Fluorescence detection of salbutamol m plasma extracts has achieved limits of detection 
ranging from 1 ng/ml [35,51,78] to sub ng/ml levels [34,46,61] Salbutamol in liver 
extracts, following I AC clean-up and separation on a Cl 8 column, has been determined 
with a limit of detection of 1 ng/g [8]
2 5 2 ELECTROCHEMICAL DETERMINATION
Electrochemical detection, m combination with HPLC, has been used to detect several (3- 
agomsts, mainly in biological fluids, at the low and sub ng/ml level Both fenoterol and 
salbutamol were determined m plasma extracts using a dual carbon electrode system [65] 
The first electrode, operating at 900 mV, was used to oxidise and detect both p-agomsts, 
while the response of the second electrode operating at 500 mV was subtracted from the 
response of the first electrode in order to enhance the signal to noise ratio of the system 
Limits of detection of 0 5 ng/ml and 1 25 ng/ml were reported for salbutamol and 
fenoterol, respectively A similar method has also been applied to salbutamol 
determination in serum samples with a limit of detection of 1 ng/ml [47] Detection 
methods involving a single carbon electrode have also been successfully applied to the 
determination of salbutamol m serum [36], plasma [66] and lyophilized rat carcass [60] 
with limits of detection of 0 8 ng/ml, 1 ng/ml and 0 1 ng/g, respectively 
An interesting combination of both UV and ECD detection systems following HPLC 
separation of clenbuterol was recently reported [40] The ratio of electrochemical to UV 
absorbance signals was used to increase specificity, but due to the progressive decrease of 
the electrochemical response, ECD detection could only be applied for a few consecutive
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analyses Clenbuterol and mabuterol have been analysed also in equine plasma using a 
carbon electrode operated at 750 mV with limits of detection of 0 5 and 2 ng/ml, 
respectively [29]
2 5 3 IMMUNOASSAY DETERMINATION
Both radioimmunoassay (RIA) and enzyme immunoassay (EIA) techniques have been 
applied to the determination of P-agomsts m biological matrices
The principle of radioimmunoassay is based on competition between a fixed amount of 
radiolabelled antigen and the analyte (present in standards or sample extracts) for binding 
to a limited amount of antibody After incubation, the free and antibody-bound fractions 
are separated and the concentration of radiolabelled material m either the antibody-bound 
or free fraction is determined If a quantity of analyte is present in either a standard 
solution or sample extract, it will compete with the labelled antigen for the limited number 
of binding sites on the antibodies present A standard curve is denved and the 
concentration of analyte in sample extracts is determined by interpolation 
EIA techniques typically involve the coating of a p-agonist specific antibody on 
microplate wells, followed by competition between the P-agomst (as analyte standard or in 
sample extract) and enzyme-labelled P-agomst for binding to the antibody After a 
washing step, the enzyme substrate is added, which forms a coloured reaction product 
The amount of antibody-bound enzyme-labelled P-agomst is quantified by absorption 
spectrophotometry at a suitable wavelength and this quantity is inversely related to the 
amount of analyte present as a standard or in a sample extract
Salbutamol has been quantified in biological fluids using both EIA and RIA techniques 
Adam et al used monoclonal salbutamol antibodies to quantify salbutamol in unne by 
RIA [79] and later by EIA [80] Polyclonal antibodies have also been used to determine
i
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salbutamol in both unne [17] and plasma [81] samples by RIA The former method used 
3H-clenbuterol as the tracer, while the latter used 3H-salbutamol Zimmer et al [93] were 
the first to use a radioimmunoassay, with a standard curve of 0-40 ng/tube, m 
pharmacokinetic studies on clenbuterol that had been administered to rats and dogs 
Delahaut et al determined clenbuterol at the sub ng/ml range m plasma, unne and faeces 
using a radioimmunoassay specific for clenbuterol [25] The antibody for this procedure 
was developed usmg the method of Yamamoto et al [83] and involved the immunisation 
of rabbits with diazotized clenbuterol human serum albumin conjugate The cross- 
reactivity of the harvested antibody relative to clenbuterol (100%) was 9%, 8% and 3% for 
terbutalme, salbutamol and cimaterol, respectively This radioimmunoassay was used in 
our laboratory to determine clenbuterol m liver samples following a matnx solid-phase 
dispersion clean-up step [82] This procedure was later adapted into a multi-residue 
method capable of determining salbutamol, clenbuterol, mabuterol, terbutalme and 
cimaterol at levels of less than 1 ng/g [19]
The literature descnbes a number of clenbuterol specific enzyme immunoassays, 
consisting of assays involving one immunogenic recogmtion and those involving two 
immunogenic recogmtions The latter method, referred to as a double antibody technique, 
was initially used by Yamamoto and Iwata [83] for the analysis of clenbuterol in plasma 
with determination by fluorescence spectrometry at 450 nm The double antibody 
technique involves the competitive bmding of clenbuterol and enzyme-labelled 
clenbuterol to antibody m solution A second antibody which binds the clenbuterol- 
specific antibodies is coated on the microplate wells and retains the clenbuterol antibodies 
(together with any bound clenbuterol or enzyme-labelled clenbuterol), while the unbound 
clenbuterol and enzyme-labelled clenbuterol are eliminated m the washing step Enzyme- 
labelled salbutamol has also been used as the competing enzyme-labelled p-agomst in the
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determination of clenbuterol m unne [41], liver [86] and animal tissues [10] The use of 
enzyme-labelled salbutamol as opposed to enzyme-labelled clenbuterol resulted in lower 
limits of detection bemg attained
Enzyme immunoassays, using a single antibody, have been used to determine clenbuterol 
in unne using either clenbuterol phosphatase [16,42] or clenbuterol horseradish peroxidase 
enzyme labels [2,24,87] The same enzyme-labelled P-agomsts have been used also in the 
analysis of liver and tissue extracts for clenbuterol, using colour forming substrates such 
as tetramethylbenzidine [2,86] and o-phenylene diamine perhydrol [24] Bucknall et al 
[86] used a salbutamol horseradish peroxidase label for the analysis of liver and unne 
extracts for clenbuterol, the lower cross-reactivity of the salbutamol horseradish 
peroxidase label, compared to the clenbuterol analyte, allowed for use of a larger sample 
size in the assay giving a low limit of detection of 0 25 ng/ml
Multi-residue P-agomst enzyme immunoassays have been applied to the analysis of unne 
samples No clean-up steps were required pnor to the EIAs, apart from dilution of the 
unne samples [87,88,89] Haasnoot et al [88] determined five p-agomsts in an enzyme 
immunoassay which used salbutamol horseradish peroxidase as the enzyme label and 
tetramethylbenzidme as the colour forming substrate Clenbuterol and mabuterol could be 
determined at the 1 ng/ml level, while terbutaline, cimaterol and salbutamol were 
detectable at the 5 ng/ml level The antibody employed in a multiresidue technique must 
have a high cross-reactivity for several p-agomsts, the higher the cross-reactivity the more 
sensitive the assay The importance of the cross reactivity of antibodies in a multi-residue 
determination is shown by the limits of detection achievable for the vanous P-agomsts 
(Table 2 3)
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Table 2 3 Cross-reactivities of antibodies used in p-agomst enzyme immunoassays and 
the corresponding limits of detection (LOD) for the various p-agomsts
P-agomst CROSS-REACTIVITY OF ANTIBODY USED
Anti-salb1”1 LOD Anti-salbi88) LOD Anti-salb[891 LOD
clenbuterol 100% 0 14 ng/g 100% 1 ng/ml 100% 0 3 ng/ml
salbutamol 115% 5% 5-10 ng/ml 28% 0 9 ng/ml
mabuterol 65% 140% 1 ng/ml 95% 0 3 ng/ml
tertbutalme 31% 4% 5-10 ng/ml 2 1% 1 3 ng/ml
cimaterol 13% 4% 5-10 ng/ml
A radioreceptor assay for the detection of clenbuterol, mabuterol and cimaterol in bovine 
unne samples based on competition for binding to p-adrenergic plasma membrane 
receptors and using a radio-labelled tracer (3H-dihydroalprenolol) has been described and 
has a limit of detection of 2 4 ng/ml for clenbuterol [26]
2 5 4 MASS SPECTROMETRIC DETERMINATION 
2 5 4 1 APPLICATIONS OF GC-MS
In comparison to classical chromatographic detection systems which rely largely on 
retention time and to immunoassays which rely on antibody analyte interaction, mass 
spectrometry provides unambiguous confirmation of the identity of the analyte(s) in a 
sample due to its ability to detect molecular ions and related fragments Combination of 
the resolving power of chromatography with mass spectrometry gives a uniquely effective 
tool for the identification and quantitation of analytes in sample extracts Tnmethylsilyl 
derivatives of clenbuterol [9,49,69] and salbutamol [48,54] have been analysed by GC-MS
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in both electron impact (El) and positive ion chemical ionization (Cl) modes N-O- 
Bis(tnmethylsilyl)-tnfluroacetamide, which was used in preparing the tnmethylsilyl 
derivatives, has also been used in multi-residue GC-MS analysis of p-agomsts
[14,20,59,70,71] Figure 2 4 shows the fragmentation patterns observed m the analysis of 
TMS derivatives of P-agomsts
Figure 2 4 Main fragmentations observed in mass spectra of p-agomst TMS derivatives
The m/z weight of fragment C is either 86 or 72 depending on whether the P-agomst 
contains a tert-butyl end group or an isopropyl end group (cimaterol) Several multi- 
residue methods focus on the detection of fragments B and C for screemng purposes
[14,20,59,71] and confirmation is based on the detection of four fragment ions [20,59,70] 
One interesting method uses a combination of results from GC-MS (El) and GC-MS (Cl) 
analyses in order to confirm p-agomst presence in sample extracts if the GC-MS (El) 
procedure cannot alone provide sufficient structural information [71] The limits of 
detection achieved with this method for feed, urine and liver were 10 ng/g, 3 ng/ml and 1 
ng/g, respectively
N-methyl-N(tert-butyldimethylsilyl)-tnfluroacetamide (MSBSTFA) has also been used to 
generate a tert-butyldimethylsilyl derivative of clenbuterol which was analysed 
simultaneously with a TMS derivative of clenbuterol by GC-MS in both the El and Cl
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mode The simultaneous analysis of two different derivatives allowed for the 
determination of four diagnostic ions at levels of 10 ng/g and above The limit of 
detection based on the m/z 86 fragment was 0 5 ng/g [49]
Hexamethyldisilazane, another TMS denvatising agent, has been used m the analysis of 
clenbuterol and salbutamol using GC-MS m the Cl mode Ammonia was used as the 
reagent gas for the analysis of clenbuterol in unne samples Single ion momtonng (SIM) 
was used to detect the clenbuterol ion [M+H]+ at m/z 349, while the internal standard ion 
D9-clenbuterol was monitored at m/z 358 [33] The same ions were momtored in a 
method for clenbuterol determination in animal tissue and feed, as well as in unne, by 
Furst et al with sub ng/g limits of detection [23] Using methane as the reagent gas, Furst 
and co workers also determined salbutamol m unne samples The salbutamol-TMS ions 
momtored were m/z 440 4, 441 4, 456 4 and 366 3 An internal standard, D9-clenbuterol- 
TMS, was monitored at m/z 358 2 and 360 2 [73]
Tnmethylsilyl denvatives of clenbuterol formed using N-methyl-N-tnmethylsilyl- 
tnfluroacetamide, have been used in the GC-MS (El mode) for the analysis of biological 
tissues and feed [53] and horse unne [58] Again, the most abundant fragment ion was 
m/z 86, but fragment ions of higher mass were momtored at m/z 334, 335, 337 and 405 for 
confirmation purposes [53] Leyssens and co workers analysed tnmethylsilyl denvatives 
of eight p-agomsts by GC-tandem mass spectrometry [6] Identification was based upon 
(1) retention time, (2) the presence of a [M+H]+ ion for each P-agomst and (3) the ratio of 
two or three fragment (daughter) ions generated by collision-induced dissociation of the 
conespondmg [M+H]+ ion GC-MS-MS techniques such as this benefit from lower 
background signals during analysis and consequently have lower limits of detection The 
disadvantage of TMS denvatives of p-agomsts is that the most abundant ions attained
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with TMS derivatives are also the ions of lowest molecular weight and this imposes 
limitations on the capacity to provide confirmatory analysis
Cyclic 2-(dimethyl)silamorpholine (CDMS) derivatives of p-agomsts have been analysed 
by GC-MS m El mode [58] and in both El and Cl modes [14] The denvatising agent, 
chloromethyldimethylchlorosilane, involves an mtra-molecular alkylation and the 
formation of a heterocycle which is stable for over one week at 4°C The use of cyclic 
DMS denvatives allowed for the detection of a large number of characteristic ions for 
thirteen P-agomsts The fragmentation patterns, using El ionization techniques, were very 
specific giving M+, [M-15]+, [M-29]+ and [M-57]+ ions and provided more informative 
data than TMS denvatives Figure 2 5 shows a cyclic DMS clenbuterol denvative
Cl “  x
C(CH3)3
Figure 2 5 Cyclic DMS denvative of clenbuterol
Boromc acid denvatives of clenbuterol have been analysed by GC-MS in El mode (Figure 
2 6) Polettim and co workers used 1-butane boromc acid for the analysis of clenbuterol m 
urine samples [27] The most abundant ions were m the high mass range at m/z 243, 327 
and 342 and the limit of detection was 0 5 ng/ml Determination of clenbuterol in liver, 
muscle, retina and unne extracts by GC-MS (El mode) was achieved using a 
methylboromc acid denvative of clenbuterol [5] The most prominent ions were m/z 243, 
285 and 300 The m/z 300 ion is the molecular ion and the m/z 285 fragment is the 
molecular ion minus a methyl group The m/z 243 fragment is due to the additional loss
(c h 3)2
Cl r\ c .
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of OBCH3 The closeness of the three 10ns and their relatively high mass allowed for 
monitoring of clenbuterol residues using single ion monitoring The detection limit for the 
method was reported at 0 05 ng/g using high resolution mass spectrometry
Cl
R=C4H9 butane boromc acid derivative, R=CH3 methyl boromc acid derivative 
Figure 2 6 Boromc acid derivatives of clenbuterol
Methylboromc acid and N-butylboromc acid derivatives of salbutamol were also analysed 
using GC-MS in El mode [74] The methylboromc acid denvative was preferred as it did 
not degrade the GC column and was easier to make The 10ns monitored were m/z 287, 
272 and 230, the first being the molecular ion while the other two 10ns resulted from the 
loss of a methyl [M-15]+ group and of methyl and OBCH3 groups [M-57]+, respectively 
Girault et al achieved very low limits of detection for clenbuterol m bovme plasma and 
tissue extracts [12] Following denvatisation with pentafluoropropiomc anhydride, 
clenbuterol and the internal standard D9-clenbuterol were measured by GC-MS in negative 
ion chemical ionization mode using methane as the reagent gas The mass spectrometer 
was set to momtor m/z 368 and m/z 377 10ns of the pentafluracyl derivatives For tissue 
samples the limit of detection was 10 pg/g Phosgene has been used also to denvatise 
clenbuterol to form a cyclic oxazolidme derivative [13] The 10ns momtored were the 
molecular ion at m/z 302 and two fragments, [M-59]+ and [M-101]+ The confirmation 
catena for the presence of clenbuterol in extracts were based upon the retention time and
r i R
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the ion ratios for samples being comparable to those for the standard material A limit of 
detection o f0 25 ng/g was achieved
2 5 4 2  APPLICATIONS OFLC-MS
Liquid chromatography coupled to mass spectrometry has been used to determine 
clenbuterol and salbutamol-sulphate in unne samples In the former case, the LC-MS was 
operated in the positive ion acquisition mode, monitoring the molecular ion at m/z 277, 
and a limit of detection of 1 ng/ml was obtained [90] Fast atom bombardment (FAB) and 
thermospray mass spectroscopy were used in the latter analysis, both m the negative ion 
momtonng mode Only thermospray proved successful, however, as too many interfering 
peaks were present with the FAB technique The ions momtored were m/z 318 and 321 
representing the [M-H]" ion for the salbutamol-sulphate and its deuterated analogue 
respectively [55]
Debrauwer et al have investigated the fragmentation patterns for clenbuterol [28] and 
other P-agomsts [91] m LC-MS systems using an electrospray interface with collision- 
induced disassociation of the charged ions formed Fragmentation patterns could be 
controlled through adjusting the voltage difference between the glass capillary transfer and 
the skimmer region The fragmentations observed mainly involved a loss of water from 
the side chain hydroxy group and cleavages at the secondary amine function 
A thermospray interface was used by Van Rhijn et al in the LC-MS-MS analysis of 
clenbuterol and other p-agomsts [92] This method momtored both the molecular ions of 
the P-agomsts and also a common fragmentation giving nse to the loss of 74 mass units 
The analysis was performed by flow injection, without a chromatographic step, resulting 
in a rapid method with simultaneous detection of a range of P-agomsts
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A variety of extraction and clean-up techniques may be used m the analysis of individual 
P-agomsts in biological matrices, but most multi-residue techniques rely on either 
immunoaffimty chromatography, mixed-mode solid-phase extraction or matrix solid- 
phase dispersion to efficiently extract both the phenolic and aniline type P-agomsts 
simultaneously
Due to differences in the spectroscopic properties of the more commonly used P-agomsts, 
(clenbuterol and mabuterol are detectable by UV spectrophometry while salbutamol and 
terbutahne are detected using spectrofluorometry), immunoassays and MS determination 
techniques are the preferred multi-residue detection methods for the analysis of P-agomsts 
in biological matrices The good sensitivity associated with immunoassay techniques has 
resulted in their widespread use m multi-residue determination procedures 
Immunoassays can determine a number of P-agomsts, depending on the cross-reactivity of 
the antiserum used, but these techniques are not confirmatory In order to provide 
sufficient information to satisfy confirmation requirments, GC-MS and LC-MS(-MS) 
techniques are used
2.6 CONCLUSION
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CHAPTER 3
APPLICATION OF SOLID-PHASE EXTRACTION TO 
THE EXTRACTION AND CLEAN-UP OF 
CLENBUTEROL FROM LIVER WITH 
DETERMINATION BY RADIOIMMUNOASSAY
47
A workshop, held in Brussels in 1987 under the auspices of the European Community, 
reviewed the use of p-agomsts in animal production [1] The species of importance were 
cattle, sheep, pigs and poultry and it was concluded that p-agomsts could be used to effect 
repartitiomng so that carcass composition was altered to give less fat and more lean 
A review by Moloney and Allen [2] found a typical increase of 10% in trimmed lean and a 
25-30% reduction in dissectable fat in the carcasses of cattle treated with p-agomsts 
during the finishing period A similar effect was seen in sheep with growth rate increasing 
by up to 29% while the percentage protein had increased by up to 18% and the amount of 
dissectable fat was reduced by up to 41% p-agomst treatment of pigs had little effect on 
carcass weight, but increased muscle growth was reported along with a 10% increase in 
trimmed lean Similarly, the effect of P-agomsts on weight gain in broilers was low 
(<5%) but the fat content was reduced by 8-10% The review concluded that p-agomsts 
improve the efficiency of carcass lean in all major meat-producmg species and that, while 
the repartitiomng effect is expressed to a greater extent in ruminants than in pigs or 
poultry, it is commercially important for all species This commercial importance has 
huge implications for the livestock trade and, even though the use of compounds with 
hormonal or thyreostatic action was prohibited within the European Community in 1986 
[3], the financial benefits to livestock producers has resulted in the illegal use of 
clenbuterol and other p-agomsts The illegal use of clenbuterol was evident m an outbreak 
of food poisomng from liver contaimng clenbuterol residues in Spain In the 135 cases 
reported clenbuterol was detected in the unne of two patients, while the concentration of 
clenbuterol in bovine liver samples was found to be as high as 291 ppb [4] Incidents 
such as these require the availability of sensitive methods capable of determining 
clenbuterol residues in edible tissue in order to protect the consumer
3.1 INTRODUCTION
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The persistence of residues of clenbuterol in tissues and body fluids of veal calves which 
had been treated with a dose of 5 |ig/Kg bodyweight twice daily for three weeks was 
studied by Meyer et al [5] The highest residue concentration of clenbuterol was found in 
the eye (118 ng/g) when no withdrawal penod had been observed and, even after a two 
week withdrawal penod, 15 ng/g was still remaining Although clenbuterol was observed 
m most other tissues immediately after termination of treatment, the only edible tissue 
showing appreciable levels of clenbuterol after a two week withdrawal penod was the 
liver (0 58 ng/g), indicating this organ to be a suitable tissue for residue analysis Elliott et 
al [6] studied the residues of clenbuterol m tissues of sheep treated with both therapeutic 
and growth enhancing concentrations and found that liver samples consistently contained 
the highest concentrations of clenbuterol
Even after a fifteen day withdrawal penod, the liver samples of the three treatment groups 
(therapeutic level, 10 x therapeutic level, 25 x therapeutic level) had mean concentrations 
of 0 59, 3 17 and 3 63 ng/g respectively, all of which are above the 0 5 ng/g maximum 
residue limit specified in the UK for clenbuterol The relatively fast rate of elimination of 
clenbuterol from other organs, such as the lungs and kidneys, in the treated sheep 
precluded these organs from being considered as suitable samples for residue analysis In 
this study the eye tissues were not analysed, but both studies showed that the highest 
accumulation of clenbuterol in edible tissues occured in the liver and that even after a two 
week withdrawal penod the level of clenbuterol found in this tissue was above the UK 
maximum residue limit The high accumulation of clenbuterol in the eye tissues is offset 
by the limited sample size available for analysis (1 g) A review of the literature relating to 
the analysis of liver samples for clenbuterol shows several references to the extraction of 
clenbuterol from homogenised liver samples using solvent extraction techniques Solvents 
such as diethyl ether [6,7] tert-butylmethylether [8,9] and ethyl acetate [10,11] have been
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used successfully to extract clenbuterol from samples adjusted to alkaline pH The 
disadvantages of classical liquid/liquid extraction (LLE) procedures for liver extractions, 
such as emulsion formation, difficulty m automation and the need for centrifugation, have 
prompted the introduction of on-column LLE procedures on diatomaceous earth 
Extractions are earned out under gravity with the aqueous liver digest or fluid sample 
being poured onto the column After an equilibration time, the organic extracting solvent 
is poured into the column and the analyte is collected On-column LLE procedures have 
already been used for the extraction of clenbuterol from vanous animal tissues and 
biological fluids Clenbuterol has been extracted from unne [12] and animal tissues [13] 
at alkaline pH on ‘ChemElut’ columns using hexane as the extracting solvent In both 
cases hydrochlonc acid was added to the hexane eluate in order to back extract and 
preconcentrate the analyte into a small volume pnor to determination Courtheyn et al 
[14] used an organic mixture of toluene dichloromethane (3 1) to extract both 
clenbuterol and cimaterol from animal tissues, faeces, feed, urine, plasma, blood and bile 
after the samples at pH 12 had been applied to ‘ChemElut’ columns The analytes were 
back extracted from the organic mixture using hydrochlonc acid pnor to their 
determination by HPLC using a post-column denvatisation step An interesting 
combination of on-column LLE of clenbuterol from unne at pH 10-11 with tert- 
butylmethylether followed by further clean-up and concentration on a C2 SPE cartridge, 
after the organic eluate had been evaporated and the sample reconstituted in borate buffer 
at pH 9 5, was reported by Hooijennk et al [15] This procedure was the first attempt to 
combme on-column LLE with a SPE clean-up and concentration step, with the only 
disadvantage of the procedure being the need for evaporation of the tert-butylmethylether 
eluate pnor to the SPE step All the other on-column LLE methods discussed relied on a
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back extraction step with hydrochloric acid m order to extract and concentrate clenbuterol 
from the organic eluate
The aim of this study was to develop a method which used an on-column LLE step to 
extract clenbuterol from the primary extract and to further clean-up and concentrate the 
sample directly on a SPE column prior to determination by radioimmunoassay
3.2 EXPERIMENTAL
3 2 1 REAGENTS AND MATERIALS
Toluene (‘Anstar’ grade), dichloromethane (‘HiPerSolv’ grade) and diethylether (‘GPR’ 
grade) were supplied by BDH (Poole, UK) Hexane (‘extra pure’) and Ethanol (‘absolute 
GR’) were obtained from Merck (Darmstadt, Germany) Other chemicals used were 
AnalaR grade from BDH, or equivalent Tns(hydroxymethyl)methylamme buffer (0 1 M, 
pH 8 0), containing 14 8 g/1 calcium chloride was used for the liver digestion and 
extraction step Protease enzyme, type XXIV (bacterial) was obtained from Sigma 
(St Louis, MO, USA)
‘ChemElut’ LLE columns (20 ml sample capacity) were obtained from Vanan (California, 
USA) and Sep-Pak silica SPE columns were supplied by Waters (Massachusetts, USA) 
Phosphate buffer (0 01 M, pH 7 0), containing 1 g/L gelatin and 0 1 g/L thiomersal, was 
used for the radioimmunoasay Dextran-coated charcoal was prepared by adding 2 g
activated charcoal (Sigma) and 0 25 g dextran T70 (Pharmacia, Uppsala, Sweden) to 500
ml doubly-distilled water The immunoassay kit used for the determination of clenbuterol 
was obtained from Laboratoire d’Hormonologie (Marloie, Belgium) The scintillation 
cocktail was Cocktail T (BDH)
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3 2 2 APPARATUS
A LKB Wallac 1219 Rackbeta liquid scintillation counter was used to count the 
radioactivity present in extracts from the on-column LLE and silica SPE procedure during 
method development and for radioimmunoassays
3 2 3 LIVER EXTRACTION PROCEDURE
Liver (1 25 g) was weighed into a 60 ml centrifuge tube 25 ml TRIS buffer (0 2 M, pH 
10) contaimng protease enzyme (0 33 mg/ml) and calcium chloride (0 1 M) was added 
Following homogemsation and digestion for one hour at 55°C with periodic mixing, the 
digest was immersed in boiling water for 15 mmutes to deactivate the enzyme The 
sample was centrifuged at 2000 rpm for 20 minutes and 20 ml of the resulting supernatant 
was collected
3 2 4 ON-COLUMN LIQUID/LIQUID EXTRACTION
The pH of the supernatant was adjusted to pH 12 using 1 6 ml 1 M NaOH The primary 
extract was applied to the ‘ChemElut’ column and allowed to equilibrate for 20 minutes 
Clenbuterol was eluted from the column with 3 x 20 ml toluene
3 2 5 SILICA SOLID-PHASE EXTRACTION
The collected toluene eluate was applied to a silica solid-phase extraction column which 
had been conditioned with 10 ml toluene The eluate was allowed to pass through the 
silica column under gravity The column was washed with 4 ml hexane and 4 ml 
acetomtnle and dried for ten mmutes under vacuum Clenbuterol was eluted with 9 ml
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ethanol The collected eluate was evaporated at 40°C under a gentle stream of nitrogen 
and resuspended in 0 5 ml ethanol
3 2 6 RADIOIMMUNOASSAY
V
0 2 ml aliquots of the liver extracts were added to culture tubes Tubes containing 1000, 
250,100, 40, 10, 0 pg clenbuterol were prepared for the standard curve The samples and 
standards were evaporated to dryness at 40°C under a stream of nitrogen and redissolved 
m 0 5 ml phosphate gelatm buffer (pH 7) After vortexing, the culture tubes were
0 3incubated at 37 C for 10 minutes 0 1 ml H clenbuterol (3000 cpm) and 0 1 ml antiserum 
were added and the culture tubes were incubated at 37°C for a further 15 minutes and 
overnight at 4°C 0 5 ml dextran-coated charcoal was added and, after shaking, the tubes 
were centrifuged at 2000 rpm The supernatants were decanted into scintillation vials and 
10 ml cocktail T was added The vials were counted for 5 minutes
3 2 7 METHOD VALIDATION
Bovine liver samples analysed as free of p-agonist residues were used for fortification 
studies To liver samples (1 25 g) 25 [i\ and 50 jil volumes of an ethanolic solution 
contaimng clenbuterol at 10 ng/ml were added to give fortification levels of 0 2 and 0 4 
ppb, respectively The fortified liver samples were left to equilibrate for 10 minutes before 
extraction
The interassay variation for determination of clenbuterol in liver was determined by 
analysis of samples, fortified at 0 2 and 0 4 ppb, on 5 different occasions The intra assay 
variation for determination of clenbuterol in liver was determined by analysis of replicate 
samples (n=6), fortified at 0 2 and 0 4 ppb, in a single assay
5 3
3 3 1 ON-COLUMN LIQUID/LIQUID EXTRACTION
Tntiated clenbuterol was used to determine which elution solvent gave the highest 
recovery of clenbuterol from the LLE column The primary extract was applied at two pH 
levels, pH 10 and pH 12, both of which are above the pKa of clenbuterol The organic 
solvents evaluated were hexane, toluene and a mixture of toluene dichloromethane (3 1)
3 x 20 ml of each solvent were used to elute clenbuterol from the primary extract which 
had been applied to the column and allowed to equilibrate for 20 minutes The tntiated 
clenbuterol present in the eluates was back-extracted into 0 2 ml hydrochlonc acid (0 1 M) 
and, following the addition of 0 01 ml of 10 M NaOH, clenbuterol was re-extracted into 
ether (6 ml) The ether samples were evaporated at 40°C under a stream of nitrogen and 
resuspended in 1 ml methanol The methanol fractions were decanted into scintillation 
vials and counted following the addition of Cocktail T (10 ml) The recovenes of 
clenbuterol are shown in Table 3 1 The highest recovenes were achieved from the 
‘ChemEluf column when the pnmary extract was adjusted to pH 12 and toluene was used 
as the extraction solvent The low recovenes obtained with hexane are due to the very 
non-polar nature of this solvent, relative to toluene, which renders it unsuitable for 
extraction of clenbuterol, even at pH 12 The low recovery at pH 10 with toluene is due to 
the pKa of clenbuterol (9 3) and the pH of the pnmary extract being very close At pH 12, 
2-3 units above the pKa of clenbuterol, the molecule exists m a non-charged state and is 
easier to extract from the ‘ChemElut’ column
3.3 RESULTS AND DISCUSSION
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Recovery of tntiated clenbuterol from primary extracts using ‘ChemElut’ columns 
under various conditions
Table 3 1
Eluent Hexane Toluene Toluene Dichloromethane (3 1)
pH 10 12 10 12 12
Recovery (%) 41 35 38 80 75
3 3 2 SILICA SOLID-PHASE EXTRACTION
The silica SPE step was required to extract clenbuterol from the toluene eluate generated 
m the on-column LLE step Solid-phase extraction with a Cl 8 type cartridge was not 
possible due to the noncompatibility of its hydrophobic retention mechanisms with 
organic solvents Silica SPE cartridges were conditioned with 10 ml toluene prior to the 
application of 60 ml toluene containing 3H-clenbuterol which was allowed to pass through 
the column under gravity The column was dried under vacuum for 10 minutes Three 
organic solvents were evaluated for their capacity to elute clenbuterol and the recoveries 
are shown in Table 3 2 Ethanol, which yielded a recovery of 88% for clenbuterol, was 
chosen as a suitable elution solvent for the silica clean-up step The silica silanol groups 
retain clenbuterol strongly, and neither acetomtnle or methanol are capable of removing 
clenbuterol from the sorbent Ethanol, however, competes effectively with the silanol 
groups retentive power Elution with ethanol is considered to be due to a combination of 
(a) the non-polar interaction of the slightly larger alkyl group of ethanol (compared with 
methanol) with clenbuterol and (b) competition between the hydroxyl moiety of ethanol
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and the silanol groups in their polar interactions with the primary and secondary ammo 
groups of clenbuterol The completed extraction and clean-up procedure yielded extracts 
suitable for determination of clenbuterol by radioimmunoassay
Table 3 2
Recovery of tntiated clenbuterol from silica SPE cartridges usmg three elution solvents
Eluent Acetomtnle Methanol Ethanol
Elution volume (ml) 9 0 9 0 9 0
Polanty index 6 2 66 5 2
Recovery (%) 07 13 0 88 0
3 3 3 METHOD VALIDATION
The inter and mtra-assay variations for the determination of clenbuterol in fortified liver 
are shown in Tables 3 3 and 3 4, respectively Both the inter and intra-assay variations 
have acceptable coefficients of variation The recoveries for clenbuterol at 0 2 ppb are 
higher than those attained at 0 4 ppb, this may be explained as the differing effect of 
matrix interference m the sample extracts at different points of the RIA standard curve 
such that the sample extracts containing lower amounts of clenbuterol are less affected 
An extract-containing standard curve would remove this effect as the matrix interference 
present m the sample extracts would also be present in the standard curve An extract- 
containing standard curve was not used in this expenment because of the large number 
(l e 7) of additional residue free control liver samples which would require processing for 
the standard curve This effect has been observed previously, such as for a MSPD method 
to extract clenbuterol from liver with determination by RIA [16] The authors reported 
similar recoveries of clenbuterol at three fortification levels when an extract contaimng
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standard curve was used, while the recovery for different fortification levels differed by 
19% when an external standard curve was used in the radioimmunoassay
Table 3 3 Inter-assay variation for SPE/RIA determination of clenbuterol in liver
Clenbuterol added (ng/g) n Clenbuterol determined
Mean ± SD (ng/g) CV (%)
02 5 0 16± 0 01 93
0 4 4 0 25 ± 0 02 6 1
Table 3 4 Intra-assay variation for SPE/RIA determination of clenbuterol in liver
Clenbuterol added (ng/g) n Clenbuterol determined
Mean ± SD (ng/g) CV (%)
02 6 0 15 ± 0 01 61
04 6 0 26 ± 0 04 164
3 3 4 INCURRED SAMPLE ANALYSIS
Liver samples from animals treated with clenbuterol were analysed by this procedure The 
concentration of clenbuterol determined by this method compares well with the results 
obtained with a standard method used in the laboratory The mean concentrations of 
clenbuterol determined with this procedure and with the standard method were 0 43 ± 
0 06 ng/g and 0 36 ± 0 05 ng/g, respectively
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3 3 5 LIMIT OF DETECTION
The limit of detection for the procedure was calculated as the mean response for twelve 
control liver samples plus three times the standard deviation
Mean response for control liver samples (n=12) 0 06 ng/g
Standard deviation about the mean 0 028 ng/g
Limit of detection 0 06 ng/g + 3 x 0  028 ng/g = 014 ng/g
The calculated limit of detection is below the UK maximum residue limit for clenbuterol 
m edible tissue (0 5 ng/g)
3.4 CONCLUSION
The technique developed has several advantages over other methods used to extract 
clenbuterol from lr'er These include the possibility of automating the extraction and 
clean-up procedure once the primary extract has been generated There is no requirement 
for centrifugation during the extraction and clean-up stage and problems with emulsions 
are eliminated through the use of ‘ChemElut’ on-column liquid/liquid extraction columns 
By developing compatible on-column LLE and silica SPE clean-up and concentration 
steps the eluate from the LLE column can be transferred directly to the SPE column 
thereby avoiding time-consuming solvent evaporation between the two clean-up steps
The suitability of this method for residue analysis is indicated by the low limit of 
detection, calculated to be 0 14 ng/g The similarity of results obtained for incurred liver 
samples by this method and a standard method indicate the applicability of this procedure 
to the analysis of clenbuterol residues in liver
The mter-assay and intra-assay variations have acceptable coefficients of variation and the 
lower recoveries at higher concentration of clenbuterol could be compensated for through
5 8
the use of an extract-containing standard curve The application of this procedure to other 
p-agonist residues, such as salbutamol and terbutaline, may result in poor recoveries due 
to the hydrophilic nature of these compounds which would reduce their recovery from the 
on-column LLE step Clean-up steps involving more than one retention mechanism, such 
as mixed phase SPE, may be more appropriate for extracting P-agomsts of a range of 
chemical characteristics and, therefore, be more suited to a multiresidue procedure
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CHAPTER 4 
MULTI-RESIDUE ANALYSIS OF (3-AGONISTS IN 
URINE AND LIVER USING MIXED-MODE SOLID 
PHASE EXTRACTION WITH DETERMINATION BY
RADIOIMMUNOASSAY
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The illegal use of p-agomsts in Europe has necessitated the introduction of multi-residue 
methods capable of determining a range of P-agomsts in a single analytical procedure 
Clenbuterol, salbutamol and mabuterol have been found m samples of unne and liver in 
The Netherlands [1], while bovine unne samples analysed m Italy were found to contain 
clenbuterol and, in one case, salbutamol residues [2] High levels of clenbuterol and 
salbutamol have also been determined in animal feed [3]
The difference in polanty between clenbuterol and salbutamol has resulted in the residue 
methods available for clenbuterol analysis being unsuitable as multi-residue techniques 
Methods involving extraction using organic solvents such as tert-butylmethylether [4,5], 
ethyl acetate [6,7] and diethyl ether [8,9] do not have the required "strength" to extract the 
more polar p-agomsts such as salbutamol and terbutaline from an aqueous environment 
Similarly, on-column liquid/liquid extraction techniques (discussed in chapter 3) result in 
low recovery of the more polar P-agomsts, while the relatively non-polar p-agomsts, such 
as clenbuterol and mabuterol, are extracted with acceptable recovery Methods reported 
for the extraction of salbutamol at the low ppb level from biological matnces involve the 
use of immunoaffimty columns and lon-pair extractions using di(2-ethylhexyl) phosphate 
(DEHP) The immunoaffimty columns used for the extraction of salbutamol from liver 
[10], human plasma [11], and lyophilized rat carcasses [12] used anti-salbutamol 
antibodies bound to sepharose gel, and no information pertaining to their effectiveness in 
extracting other P-agomsts was presented The extraction of polar drugs from biological 
matnces by converting them into a neutral ion-associating complex by addition of DEHP 
has proved to be a useful approach in the extraction of salbutamol Hutchings et al [13] 
initially reported an assay for salbutamol that used an lon-pair extraction and 
determination by HPLC with detection by means of the drug’s inherent fluorescence The
4.1 INTRODUCTION
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ion-painng agent (DEHP) has since been used to assist the extraction of salbutamol from 
human serum [14] and plasma with determination by HPLC with fluorescence detection 
[15,16]
The non-compatibility of the existing analytical techniques used to extract either aniline 
type or phenolic type p-agomsts has resulted in the development of multi-residue 
techniques capable of extracting both types of p-agomst simultaneously These multi- 
residue techniques can be divided into three classes matrix solid-phase dispersion 
(MSPD), lmmunoaffimty chromatography (IAC), and mixed-mode solid-phase extraction 
techniques
Matrix solid-phase dispersion, was developed by Barker and co-workers [17,18] for the 
analysis of pesticide, antibiotic and other veterinary drug residues m biological matrices 
It involves manual blending of the tissue sample with octadecylsilane (C l8) matenal, 
packing the resulting matenal mto a column, and washing of the column to remove 
interferences pnor to elution of the residue(s) from the column The technique has been 
applied to the analysis of clenbuterol m bovme liver with determination by 
radioimmunoassay [19] and enzyme immunoassay [20] and was successfully applied to 
the analysis of four P-agomsts in liver with detection by radioimmunoassay [21] With 
this procedure, clenbuterol, salbutamol, and mabuterol were detectable at 1 ng/g and 
terbutalme was detectable at 2 ng/g The limit of detection was reported to be 0 7 ng/g 
Both lmmunoaffimty chromatography and mixed-mode solid-phase extraction have been 
discussed in Chapter 2 Previous work with mixed-mode SPE columns have given low 
recovery, generally, of phenolic type p-agomsts compared with aniline type p-agomsts 
[22-25]
The aim of this study was to investigate if equivalent recovery for both types of p-agomsts 
could be obtained using mixed-mode SPE Another mixed-mode SPE column
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(‘XtrackT’), previously used in the extraction of cocaine and its major metabolite from 
neonatal urine [26], was evaluated for the extraction of four P-agomsts from unne and 
liver with determination by radioimmunoassay
4.2 EXPERIMENTAL
4 2 1 REAGENTS AND MATERIALS
Ethyl acetate ('pesticide' grade), methanol ('Hipersolv' grade) and ammonia solution (35%, 
'Analar' grade) were from BDH (Poole, UK) 2-Propanol ('HPLC' grade) was supplied by 
Aldnch (Poole, UK) and ethanol ('absolute GR') was obtained from Merck (Darmstadt, 
Germany) Other chemicals used were Analar grade from BDH, or equivalent Sue 
d'Helix pomatia (containing 100,000 units p-glucuromdase and 1,000,000 units sulphatase 
per ml) was supplied by Sepracor (Villeneuve la Garenne, France) Protease enzyme, type 
XXIV (Bacterial), was obtained from Sigma (St Louis, USA) XtrackT mixed-mode 
solid-phase extraction columns (500 mg sorbent) were supplied by Technicol (Stockport, 
UK) The immunoassay kit used for the determination of P-agomsts was obtained from 
Laboratoire d'Hormonologie (Marloie, Belgium), with antiserum which had been raised 
against salbutamol and had principal cross-reactivities of 100% - salbutamol, 118% - 
clenbuterol, 78% - mabuterol, and 29% - terbutalme
For the radioimmunoassay, phosphate buffer (0 01 M, pH 7 0), containing 1 g/L gelatin 
and 0 1 g/L thimerosal was used Dextran-coated charcoal was prepared by adding 2 g 
activated charcoal (Sigma) and 0 25 g dextran T70 (Pharmacia, Uppsala, Sweden) to 500 
ml doubly-distilled water The scintillation cocktail was Cocktail T (BDH) Clenbuterol 
hydrochloride, salbutamol and terbutalme were obtained from Sigma (St Louis, MO, 
USA) Mabuterol was provided as a gift by Laboratoire d’Hormonologie (Marloie, 
Belgium)
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4 2 2 EQUIPMENT
A LKB Wallac 1219 Rackbeta liquid scintillation counter was used to count radioactivity 
4 2 3 EXTRACTION, LIVER SAMPLES
Liver (2 g) was weighed into a 60 ml centrifuge tube 10 ml TRIS buffer (0 2 M, pH 10) 
containing protease enzyme (0 33 mg/ml) and calcium chloride (0 1 M) were added 
Following homogenisation and digestion for one hour at 55°C with periodic mixing the 
digest was centrifuged for 20 minutes at 2000 rpm 5 ml of the supernatant was collected,
1 8 g sodium chloride was added and the pH was adjusted to pH 11 5 ml ethyl
acetate isopropanol (6 4) was added to the liver extract and the solution was mixed on a 
horizontal shaker for 15 mm The sample was centrifuged (2000 rpm, 15 min) and a 4 ml 
aliquot of the organic phase was collected This step was repeated and the combined 
organic phases (8 ml) were evaporated at 40°C under a gentle stream of nitrogen
4 2 4 MIXED-MODE SOLID-PHASE EXTRACTION
6 ml phosphate buffer (0 1 M, pH 6 0) was added to the unne sample (5ml) and to the 
dried liver extract (equivalent of 0 67g liver) and, where necessary, the pH was adjusted to 
pH 6 0 The XtrackT column was conditioned by the addition of 5 ml methanol, 5 ml 
doubly-distilled water and 2 ml phosphate buffer (0 1 M, pH 6 0) The sample was 
applied at a rate of 2 ml/min and the column was dned for 10 minutes under vacuum The 
column was washed with 5 ml water and with 5 ml methanol, and the column was dned 
under vacuum for 15 minutes The (3-agomsts were eluted from the column using 5 ml 
methanol containing 2% ammonia The collected eluate was evaporated at 40°C under a
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gentle stream of nitrogen and the residue was resuspended in 2 ml ethanol (liver) or 5ml 
ethanol (unne)
4 2 5 RADIOIMMUNOASSAY
/
0 2 ml aliquots of liver and unne extracts were added to culture tubes 0 2 ml aliquots of 
control (residue-free) liver or unne extracts were added to culture tubes containing a 
clenbuterol standard at 0, 10, 40, 100, 250, 1000 pg for the standard graph and to culture 
tubes containing 500 and 200 pg (liver extract) and 1000 and 400 pg (unne extract) each 
of clenbuterol, salbutamol, mabuterol or terbutaline The samples, standards and (3- 
agomst recovery standards, prepared in duplicate, were evaporated to dryness under a 
stream of nitrogen and redissolved m 0 5 ml phosphate gelatin buffer (pH 7 0) After 
vortexing, the culture tubes were incubated at 37°C for 10 minutes 0 1 ml 3H-clenbuterol 
(7500 cpm) and 0 1 ml antiserum were added, and the culture tubes were incubated at 
37°C for a further 15 minutes and overnight at 4°C 0 5 ml of dextran-coated charcoal was 
added and the tubes were centnfuged for 10 min at 2000 rpm The supernatants were 
decanted into scintillation vials and 10 ml cocktail T added The vials were counted for 5 
minutes
4 2 6 METHOD VALIDATION
Bovine unne and liver samples assayed as free of p-agomst residues were used for 
fortification studies To unne samples (5 ml) 10 jal and 25 \i\ volumes of an ethanolic 
solution containing clenbuterol, salbutamol, mabuterol or terbutaline at 1 jig/ml were 
added to give fortification levels of 2 ppb and 5 ppb, respectively To liver samples (2 g) 
10 |il and 25 i^l volumes of an ethanolic solution containing the four P-agomsts at 0 4
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mg/ml were added to give fortification levels of 2 ppb and 5 ppb, respectively The 
fortified samples were left to equilibrate for 10 minutes before extraction
4.3 RESULTS AND DISCUSSION
4 3 1 MIXED-MODE SPE COLUMNS
These columns contain two retention mechanisms based on octyl and benzene sulphomc 
acid groups bound to the silica particles The cation exchange properties of the column 
coupled with its hydrophobic retention characteristics allow for retention of a range of 0- 
agomsts The optimum pH for the extraction of p-agomsts was found to be pH 6 0, and 
the elution of these compounds occurred when methanol containing 2% ammonia was 
applied to the column An important characteristic of this column is that a pre-elution 
wash with 100% methanol is possible which results in cleaner sample extracts, a 
methanol wash on a conventional reversed-phase (C l8) SPE column would elute the 
analytes together with interferences
4 3 2 CLEAN-UP OF LIVER EXTRACTS
The application of liver extracts, following protein precipitation with HC1 and 
centrifugation, directly to the mixed-mode SPE column was not successful due to the 
amount of matrix interferences still present Studies using liver extracts fortified with 3H- 
clenbuterol and 3H-salbutamol yielded recoveries of less than 30% m the elution step from 
the SPE columns Two published solvent extraction procedures for p-agonists were 
evaluated, tert-butanol ethyl acetate (3 7) [24] and ethyl acetate isopropanol (6 4) [26], 
the latter solvent mixture was chosen because of the higher recovenes achieved The effect 
of pH and ionic strength of the aqueous liver extract on the efficiency of the extraction of
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salbutamol was investigated (Table 4 1) The saturation of the aqueous layer with sodium 
chloride prior to the extraction with ethyl acetate isopropanol resulted in good recovery of 
salbutamol at all pH values Saturation of the aqueous layer also resulted in the formation 
of a well-defined interface during the extraction procedure particularly for the 
enzymatically-digested liver extracts The use of HC1 as an alternative to enzymatic 
digestion for the preparation of liver extracts resulted m emulsion formation at the solvent 
extraction stage
Table 4 1 Extraction of Salbutamol (5 ppb) from an aqueous solution at different pH
and sodium chloride levels
P-agomst pH Sodium Chloride concentration 
(g/ 5 ml)
Recovery
(%)
Salbutamol 2 00 38
08 77
1 8 91
7 00 90
08 70
1 8 91
10 00 74
08 70
1 8 88
12 00 58
08 64
1 8 74
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An increase in the non-specific binding (NSB) in the radioimmunoassay is caused by 
sample extract, particularly liver extract even after the mixed-mode SPE clean-up Mean 
NSB figures for extract-free buffer, urine extract in buffer and liver extract in buffer are 
130 cpm (n=5), 183 cpm (n=8) and 672 cpm (n=9), respectively Good quantitive 
measurement was obtained, therefore, by preparing the standard curve (clenbuterol) for 
both unne and liver assays in residue-free sample extract
To allow for the variation m specificity of the antibody for the four p-agorusts, individual 
standards at an appropriate concentration for each analyte were prepared in residue-free 
sample extract and assayed with the samples
The inter and mtra-assay variation of the method for unne and liver are shown in Tables 
4 2 to 4 5 Good recovenes for all four P-agomsts are achieved from both unne and liver 
at fortification levels of 2 and 5 ng/g (Tables 4 2 ,4  4) The high vanability for recovery of 
mabuterol and terbutahne in unne (Table 4 2) may be due to the relatively lower cross- 
reactivity of the antibody for the P-agomst The cross-reactivity of the antiserum for 
terbutahne (29%) determined the lowest fortification level at which the method could be 
validated for all four P-agomsts under identical expenmental conditions The method is 
sensitive to lower levels of clenbuterol, salbutamol and mabuterol The mtra-assay 
vanations for unne and liver demonstrate good repeatability of the method for unne and 
liver assays (Tables 4 3 ,4 5)
4 3 3 METHOD VALIDATION
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Table 4 2 Inter-assay variation for recovery of clenbuterol, salbutamol, mabuterol and
terbutaline m unne (n=5)
ß-agomst Concentration
(ng/ml)
Range Recovery (%) 
Mean ± SD CV
Clenbuterol 2 75-92 84 ± 6 0 152
5 77-106 92 ± 10 4 113
Salbutamol 2 73-93 85 ± 83 9 7
5 62-86 76 ± 10 8 14 3
Mabuterol 2 46-95 79 ± 20 6 26 2
5 89-102 98 ± 5 3 55
Terbutaline 2 48-108 81 ± 2 7  2 33 4
5 64-106 82 ± 18 0 21 0
Table 4 3 Intra-assay variation for the recovery of clenbuterol, mabuterol, salbutamol, 
and terbutaline in unne (n=4)
ß-agomst Concentration
(ng/ml)
Range Recovery (%) 
Mean ± SD CV
Clenbuterol 2 73-80 77 ± 3 6 46
5 86-89 87 ± 1 3 14
Salbutamol 2 55-68 65 ± 73 114
5 70-86 77 ± 68 88
Mabuterol 2 84-91 90 ± 4 6 5 1
5 87-92 9 1 + 2 5 28
Terbutaline 2 48-78 69 ± 14 0 20 0
5 85-100 9 4 + 7 0 74
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Table 4 4 Inter-assay variation for the recovery of clenbuterol, mabuterol, saibutamol,
and terbutaline in liver (n=5)
ß-agomst Concentration
(ng/ml)
Range Recovery (%) 
Mean ± SD CV
Clenbuterol 2 86-116 92 ± 14 1 15 0
5 70-108 93 ± 14 3 154
Saibutamol 2 80-124 108 ±17 7 154
5 99-120 109 ± 8 0 73
Mabuterol 2 85-116 100 ± 1 1 2 112
5 82-108 94 ±10 4 11 1
Terbutaline 21 78-119 100± 15 0 15 0
5 80-103 9 6 ± 92 96
*n=4
Table 4 5 Intra-assay vanation for the recovery of clenbuterol, saibutamol, mab
and terbutaline m liver (n=4)
ß-agomst Concentration Range Recovery (%)
(ng/ml) Mean ± SD CV
Clenbuterol 2 87-99 92 ± 59 64
5 81-99 9 0 + 8 2 90
Saibutamol 2 77-117 93 ± 17 7 18 0
5 89-94 93 ± 2 5 2 7
Mabuterol 2 80-93 86 ± 56 65
5 83-97 89 ± 6 0 67
Terbutaline 21 88-123 110 ± 1 7 0 153
i
5 62-81 73 ± 82 11 2
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4 3 4 LIMIT OF DETECTION
The limit of detection of the procedure was calculated from the mean response for control 
liver and unne samples plus three times the standard deviation
(a)unne
Mean response for control unne samples (n=5) 0 024 ng/ml
Standard deviation about the mean 0 034 ng/ml
Limit of detection 0 026 ng/ml + 3 x0  034 ng/ml = 013 ng/ml
(b) liver
Mean response for control liver samples (n=8) 0 075 ng/g
Standard deviation about the mean 0 128 ng/g
Limit of detection 0 075 ng/g + 3 x 0  128 ng/g = 0 46 ng/g
The calculated limits of detection for unne and liver samples are at or below the UK 
maximum residue limit for clenbuterol
4 3 5 INCURRED LIVER ANALYSIS
Incurred liver samples with residue concentrations (determined by alternative methods) of 
4 0 ng/g clenbuterol, 3 5 ng/g mabuterol and 8 0 ng/g salbutamol, respectively, were 
assayed Good agreement was found for concentrations of clenbuterol (4 3 ng/g) and 
mabuterol (4 7 ng/g) determined by this method but a considerably lower level of 
salbutamol (13 ng/g) was determined The lower level of salbutamol determined is likely 
due to the occurrence of salbutamol largely as a conjugated residue Studies on the 
metabolism of salbutamol in farm animals have shown that salbutamol is metabolised into 
both glucuromde [29] and sulfate conjugates [27] These residues are very polar and 
essentially not extractable into organic solvents and this would explain the low level of 
salbutamol determined An enzymic deconjugation step was introduced into the method
7 3
Sue d'Helixpomatia was chosen for the hydrolysis step as it contains both P-glucuromdase 
and sulphatase enzymes which should therefore deconjugate both the glucuromde and 
sulfate metabolites of salbutamol The deconjugation step mvolved the addition of 0 66 
ml sue d'Helix pomatia (diluted 1 10) to 5ml liver digest supernatant which was adjusted 
to pH 5 0 and incubated overnight at 37°C, pnor to solvent extraction and mixed mode 
SPE as described With this modification a salbutamol residue concentration of 9 0 ng/g 
was determined in the sample
4 3 6 CHOICE OF MIXED-MODE SOLID-PHASE EXTRACTION 
COLUMNS AND IMPORTANCE OF COLUMN PARTICLE SIZE
Due to the hydrophilic character of terbutahne and its biphenol-hke structure (Figure 1 1), 
it was found that the application of terbutalme-contaimng unne samples to the mixed- 
mode sohd-phase extraction columns at a rate in excess of 0 5 ml/min resulted in 
significantly reduced recovery of the compound (Table 4 6) The effect of rate of 
application of samples (1 ml/mm) versus recovery was not as pronounced for cienbuterol, 
salbutamol or mabuterol due to their lower polarities XtrackT columns containing the 
same material, but of different particle size, were investigated also for their effectiveness 
in retaimng terbutahne in unne samples at an application rate of 0 5 ml/mm No 
significant difference in recovery of terbutahne due to particle size was observed
\
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Table 4 6 Comparison of the recovery of terbutalme from unne using XtrackT columns of 
different particle size and at different rates of sample application
Terbutalme Sample XtrackT Recovery (%)
application rate particle size
( ng/ml) (ml/mm) (pm) Mean ± SD CV
2 05 125-210 82* ± 2 7 3 2
05 40-50 691 ± 1 4  0 20 0
20 40-50 212 ± 144 68 5
5 05 125-210 931 ± 7 6 81
05 40-50 941 ± 7 0 74
I1 it  r
2 0 40-50 412 ± 20 5 50 2
Within each fortification level, mean recovery values with different superscripts
are significantly different (p<0 01)
4.4 CONCLUSION
The described method is suitable for the extraction and determination of p-agomsts in 
both bovme unne and liver samples The recovery of phenolic type p-agomsts 
(salbutamol and terbutalme) from fortified liver samples, at greater than 78%, is 
substantially higher than the recovenes reported by Leyssens et al (terbutalme - 20% and 
salbutamol - 35%), for the analysis of bovine liver [23] Similarly, the average recovery 
for salbutamol and terbutalme from fortified unne samples, at greater than 65%, is higher 
than the recovenes reported by Montrade et al (terbutalme - 36%, salbutamol - 22%) for 
the analysis of unne [24] The high recovery of both types of P-agomsts (phenolic and 
aniline) from both matnces, indicates the suitability of this method as a multi-residue 
procedure
The need for an enzymic deconjugation step is shown by the increase m the level of 
salbutamol determined in an incurred sample after deconjugation with sue d'Helix 
pomatia Due to the limited cross-reactivity of the antibody used in the immunoassay 
step, only four P-agomsts could be determined but if a detection technique such as GC- 
MS was used a wider range of P-agomsts could be determined
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CHAPTER 5
STUDIES ON THE DEVELOPMENT OF A MIXED­
MODE MATRIX SOLID-PHASE DISPERSION 
PROCEDURE FOR THE EXTRACTION OF 13- 
AGONIST RESIDUES FROM LIVER WITH 
DETERMINATION BY RADIOIMMUNOASSAY
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Matrix solid phase dispersion (MSPD) has been applied successfully, since its 
development by Barker et al [1], to the extraction of individual veterinary residues such as 
ivermectin [2,3], furazolidone [4] and chloramphenicol [5] and also in multi-residue 
extraction procedures for sulphonamides [6], chlorinated pesticides [7], benzimidazoles 
[8] and tetracyclines [9] from complex biological matrices such as liver, muscle and milk 
The technique has been used in our laboratory to extract clenbuterol from bovine liver 
samples with determination by RIA [10] and El A [11] and also in the extraction of several 
p-agomsts including clenbuterol, salbutamol, mabuterol, terbutalme and cimaterol from 
bovine liver samples [12,13] The technique involves a manual blending of tissue sample 
with octadecylsilane material using a mortar and pestle for a short penod of time (typically 
40 seconds) The blending disrupts cell membranes m the sample allowing solubilization 
of the lipophilic regions into the C l8 material The resulting mixture is packed mto a 
column and sample components are eluted sequentially using solvents of varying polarity
More recently, mixed-mode solid-phase extraction columns have been used for the 
extraction of a variety of P-agomsts from urine and liver samples [14-17] Mixed-mode 
SPE columns contain two retention mechanisms based on octyl and cation exchange 
groups bound to the solid support The cation exchange properties of the column coupled 
with its hydrophobic retention characteristics allow for retention of a range of p-agomsts 
An important characteristic of these columns is that a pre-elution wash with 100% 
methanol is possible which results in cleaner sample extracts, a methanol wash on a 
conventional reversed-phase (C l8) SPE column would elute the analytes together with 
interferences
The aim of this study was to evaluate a similar mixed-mode approach with the MSPD 
procedure by introduction of an ion-exchange step in order to determine if the
5.1 INTRODUCTION
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combination of both techniques would allow for a more exhaustive clean-up of the liver 
samples The potential advantage of the combined technique (MSPD/IE) was the speed of 
a MSPD extraction coupled with the selective retention and clean-up capabilities of the 
ion exchange step Propylsulphomc acid (PRS) was the ion exchange sorbent chosen as it 
is a strong cation exchanger and consequently is suited to the extraction of basic 
compounds such as P-agomsts from liver samples The initial method development 
involved optimising the amount of PRS material to use m the mixed-mode MSPD step, 
using tntiated clenbuterol and salbutamol The use of tntiated P-agomsts allowed for 
accurate determinations of analyte breakthrough in the washing stages and final recovery 
in the elution solvents The PRS sorbent was then applied in conjunction with reversed- 
phase sorbents m the MSPD procedure for the extraction of clenbuterol and salbutamol 
from liver samples, with determination by radioimmunoassay
5.2 EXPERIMENTAL
5 2 1 REAGENTS AND EQUIPMENT
Ammonia solution, 35% (‘AnalaR’ grade), methanol (‘HiPerSolv’ grade) and glacial 
acetic acid (‘ AnalaR’ grade) were obtained from BDH (Poole, UK) Other chemicals used 
were o f ‘Analar’ Grade or equivalent
The bulk sorbents used in the MSPD/IE step, endcapped (EC) C l8 and C8, 
monofunctional (MF) C l8, non-endcapped C l8, and propylsulphomc acid (PRS) were 
supplied by International Sorbent Technology Ltd , Cambridge, UK 
The immunoassay kit used for the determination of p-agomsts was obtained from 
Laboratoire d’Honnonologie (Marloie, Belgium) and the antiserum had principal cross- 
reactivities of 118%, 100%, 78% and 29% for clenbuterol, salbutamol, mabuterol and
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terbutalme, respectively Tntiated clenbuterol and salbutamol, also obtained form 
Laboratoire d'Hormonologie, were used in the method development stages 
Phosphate buffer (0 01M, pH 7 0) containing 1 g/1 gelatin and 0 1 g/1 thimerosal, was used 
for the RIA Dextran-coated charcoal was prepared by adding 2 g of activated charcoal 
(Sigma, St Louis, U S A )  and 0 25 g of dextran T70 (Pharmacia, Sweeden) to 500 ml of 
doubly-distilled water The scintillation cocktail was Cocktail T (BDH) Clenbuterol 
hydrochloride and salbutamol were obtained from Sigma 
5 2 2 EQUIPMENT
A LKB Wallac 1219 Rackbeta liquid scintillation counter was used to count radioactivity 
5 2 3 EXTRACTION, LIVER SAMPLES
Liver samples (0 5 g), assayed as being free of p-agonist residues, were weighed into glass 
mortars To the liver samples, 10 |il volumes of ethanohc solutions containing clenbuterol 
and salbutamol at concentrations of 2 5 jag/ml were added to give fortification levels of 50 
ng/g Fortification of liver samples with tntiated clenbuterol and salbutamol was 
performed by pipetting 10 jal of the relevant ethanohc solution (equivalent to 20,000 cpm) 
onto the samples All fortified samples were left to equilibrate for 10 minutes before 
extraction
The samples were blended with 2 g of bulk sorbent (EC C18 or C8, MF Cl 8 or non-EC 
Cl 8) for forty seconds before the addition of ion exchange matenal PRS matenal (0 25, 
0 5 and 1 0 g) was added to the sorbent/tissue blend and mixed with a spatula for 30 
seconds Any clusters of matenal were dispersed using a spatula until a homogenous 
mixture was obtained The resulting blend was transferred to a 10 ml synnge barrel 
containing two filter paper discs
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5 2 4 COLUMN ACTIVATION AND WASHING
Acetic acid, 50 mM (15 ml) was added to the blend and was brought through under 
vacuum Methanol (8 ml) was applied to the column and brought through under increased 
vacuum The blend was dried for 15 minutes under vacuum before the elution solvent (8 
ml) of 2% to 10% ammonia in methanol was applied
5 2 5 DETERMINATION
(a) Method development, based on fortification with tntiated clenbuterol or salbutamol 
For the initial method development 1ml aliquots of the final eluate and of the preceedmg 
washes, from samples which had been fortified with tntiated clenbuterol or salbutamol, 
were counted in 10ml cocktail T scintillation fluid Control (non-fortified) liver extracts, 
which had been processed under similar conditions, were spiked with tntiated matenal 
immediately before counting and the counts obtained were taken as a reference value for 
quantification of the breakthrough of analyte in the washing stages and the final recoveiy 
in the elution solvent
(a) Method validation, based on fortification with tntiated clenbuterol or salbutamol at 50 
ng/g
The MSPD/IE elution solvent was evaporated at 60°C under a stream of nitrogen and the
extracts were reconstituted in 6 25 ml phosphate gelatin buffer Following vortexmg and 
somcation, 0 05 ml of the liver extracts (equivalent to 200 pg of clenbuterol or salbutamol) 
were added to culture tubes containing 0 45 ml of phosphate gelatin buffer 0 05 ml of 
control liver extracts were added to culture tubes contaimng a salbutamol standard at 0, 
10, 40, 100, 250 and 1000 pg for the standard curve, and to culture tubes containing 200
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pg of clenbuterol and salbutamol standards in 0 05 ml phosphate gelatm buffer (recovery 
standards) To the salbutamol standard curve and the P-agomst recovery standards, 0 45 
ml and 0 40 ml aliquots of phosphate gelatm buffer was added, respectively, bringing the 
final volume of the sample extracts, standard curve and the p-agomst recovery standards 
to 0 5 ml After vortexing, the tubes were incubated at 37°C for ten minutes 0 1 ml of 3H- 
clenbuterol (8000 cpm) and 0 1 ml of antiserum were added, and the tubes were incubated 
at 37°C for a further 15 minutes and overnight at 4°C 0 5 ml of dextran-coated charcoal 
was added and the tubes were centrifuged for 10 mm at 2000 rpm The supernatants were 
decanted into scintillation vials and 10 ml cocktail T was added The vials were counted 
for 5 minutes
5.3. RESULTS AND DISCUSSION
5 3 1 SELECTION OF THE AMOUNT OF PROPYL SULPHONIC ACID 
The initial method development focused on determining a suitable amount (g) of PRS 
material for the MSPD/IE step The required amount of PRS was that which retained the 
P-agomsts during the washing stages and allowed for their elution upon the addition of 
methanol containing ammonia Three amounts of PRS material (0 25, 0 5 and 1 0 g) were 
investigated m combination with 2 g of C l8 EC bulk sorbent The Cl 8 EC was chosen 
for this evaluation because, as it is the least polar of the reversed-phase sorbents under 
study, the îomc retention characteristics of the PRS material would be m greatest demand 
The other reversed-phase sorbents would contnbute more to analyte interactions due to 
their higher polarity The amount of PRS sufficient for retention of P-agomsts using Cl 8 
EC material was judged to be adequate for sorbents of higher polarity 3H-clenbuterol and 
3H-salbutamol were used m this study to track P-agomst breakthrough in the washing 
stages and P-agomst recovery in the elution stage Profiles of the breakthrough and final
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recovery of the clenbuterol and salbutamol in the washing and elution solvents are shown 
m Figures 5 1 and 5 2, respectively All determinations were earned out m duplicate 
(Tables 5 1 and 5 2)
There is little breakthrough of clenbuterol in the acetic acid and methanol washing steps at 
any of the PRS amounts under investigation This effective retention may be attnbuted to 
the presence of two amino groups (one alkyl, one aromatic) on the clenbuterol molecule 
which interact with the cation exchange sorbent An elution solvent of 2% ammonia in 
methanol does not have the required strength to fully elute clenbuterol from the MSPD/IE 
blend, particulanly when Ig of PRS sorbent is used Concentrations of ammonia in 
methanol of 4 and 6 % are effective in substantially eluting clenbuterol (i e >89 %) at the 
three amounts of PRS used and the highest recovery of clenbuterol is obtamed with a I g 
quantity of PRS and an elution solvent of 6% ammonia in methanol 
Higher sample breakthrough values are observed for salbutamol m the acetic acid washes 
particularly when using less than 1 g of PRS matenal The percentage breakthrough of 
salbutamol when using 0 25, 0 5 and 1 g PRS sorbent were 23, 19 and 9%, respectively 
The high breakthrough of salbutamol at lower amounts of PRS matenal may be due to an 
insufficient amount of the cation exchange sorbent being present to fully retain the (3- 
agomst Salbutamol has two hydroxy groups on the aromatic nng and, therefore, is quite 
polar, this hydrophilic character coupled with the molecule having only one ammo group 
for ionic interactions with the cation exchanger may explain the high sample breakthrough 
of salbutamol in the acetic acid washes at low amounts of PRS matenal Very little 
salbutamol breakthrough is observed in the methanol wash of the MSPD/IE columns The 
highest recovery of salbutamol is achieved using lg PRS and an elution solvent of 4 to 6
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Figure 5 1 Profile of breakthrough and recovery of 3H-clenbuterol m the washing and
elution solvents for each of the three amounts of PRS sorbent used in 
combination with 2 g C l8 EC bulk sorbent
Acetic Acid Methanol 2%NH3 4%NH3 6%NH3
Table 5 1 Breakthrough and final recovery of H-clenbuterol in the washing and elution 
solvents for each of the three amounts of PRS material used in combmation
with 2 g C l8 EC bulk sorbent
PRS (g)
Recovery (%)
Acetic Acid Methanol 2% NH3 in 
MeOH
4% NH3 in 
MeOH
6% NH3 in 
MeOH
0 25 4 4 77 93 89
05 5 5 87 89 95
100 5 6 48 90 101
8 6
Figure 5.2 Profile of breakthrough and recovery of 3H-salbutamol in the washing and 
elution solvents for each of the three amounts of PRS material used in 
combination with 2 g Cl 8 EC material.
Acetic Acid Methanol 2%NH3 4% NH3 6% NH3
Table 5.2 Breakthrough and final recovery of 3H-salbutamol in the washing and elution
solvents for each of the three amounts of PRS material used in combination 
with 2 g C l8 EC sorbent.
PRS (g)
Recovery (%)
Acetic Acid Methanol 2% NH3 in 
MeOH
4% NH3 in 
MeOH
6% NH3 in 
MeOH
0.25 23 3 68 66 74
0.50 19 3 73 82 76
1.00 9 3 49 100 90
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% ammonia in methanol The low recoveries of salbutamol observed for the blends 
containing 0 25 g and 0 5 g PRS matenal are explained by the loss of salbutamol m the 
initial acetic acid washing steps Figures 5 1 and 5 2 show that lg  of PRS matenal used m 
combmation with an elution solvent of 4 % ammonia or greater yields the highest 
recovenes for both p-agonists with minimal breakthrough in the washing steps
5 3 2 SELECTION OF REVERSED-PHASE SORBENT
The relative retention and clean-up charactenstics of four reversed-phase sorbents (C l8 
EC, C8 EC, C l8 and MF C l8) were assessed, m combmation with a 1 g amount of PRS 
sorbent, for the extraction of salbutamol and clenbuterol from fortified liver samples 
Liver samples fortified at 50 ng/g were used to assess the performance of the four sorbent 
types and the appropnate concentration of ammonia required for the elution of the analytes 
from the MSPD/IE blend Good quantitative measurement was obtained by prepanng the 
salbutamol RIA standard curve in residue-free sample extract To allow for the vanation 
in specificity of the antibody for the two P-agomsts, individual standards (recovery 
standards) at the appropnate concentration for each analyte (200 pg) were prepared in 
residue-free sample extracts and assayed with the samples Profiles of the the recovery of 
clenbuterol and salbutamol from the four sorbent types using five concentrations of 
ammonia in methanol (ranging from 2 to 10 %) are shown m Figures 5 3 and 5 4, 
respectively All determinations were earned out m duplicate (Tables 5 3 and 5 4) 
Highest recovery of clenbuterol is obtained with MF C l8 at ammonia concentrations of 
4% or higher and with C l8 EC and C8 EC sorbents at 6% or higher, while relatively poor 
recovery is obtained with the C l8 sorbent at all concentrations of ammonia The most 
polar sorbent, non-endcapped C l8, substantially retains clenbuterol on the MSPD/IE 
column on elution with 2% ammonia in methanol and, even at concentrations of 4%
8 8
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Figure 5 3 Profile of the recovery of clenbuterol from four reversed-phase sorbents, in 
combination with lg PRS ion-exchange sorbent, on elution at different 
concentrations of ammonia in methanol
C l8 EC C18 MFC18 C8 EC
Table 5 3 Recovery of clenbuterol from four reversed-phase sorbents, in combination 
with 1 g PRS ion exchange sorbent, on elution at different concentrations of 
ammonia in methanol
Ammonia in methanol (%) Recovery (%)
C18EC C18 MF Cl 8 C8 EC
2 65 23 14 36
4 65 42 77 61
6 80 57 72 73
8 77 56 76 72
10 78 60 79 67
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Figure 5 4 Profile of the recovery of salbutamol from four reversed-phase sorbents, in 
combmation with lg PRS ion-exchange sorbent, on elution at different 
concentrations of ammonia m methanol
Cl 8 EC C18 MF Cl 8 C8 EC
Table 5 4 Recovery of salbutamol from four reversed-phase sorbents, in combmation 
with lg PRS ion exchange sorbent, on elution at different concentrations of 
ammonia in methanol
Ammonia in methanol (%) Recovery (%)
Cl 8 EC C18 MFC18 C8 EC
2 42 29 25 37
4 57 39 62 71
6 73 50 75 62
8 87 63 60 78
10 70 56 69 69
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ammonia and above, the combmed retention capacity of the reversed-phase and ion 
exchange sorbents are only partially overcome Monofunctional C18 sorbent shows 
strong discrimination between an eluent containing 2 % ammonia and eluents contaimng 4 
% or higher ammonia, this discrimination may be useful m developing a clean-up step in 
the procedure The C l8 EC sorbent, the least polar of all the bulk sorbents, yields a 
consistently high recovery of clenbuterol at all concentrations of ammonia m methanol 
and is, therefore, the preferred sorbent for use in a mixed-mode MSPD extraction of 
clenbuterol from liver
Highest recovery of salbutamol was obtained with MF C18, C18 EC and C8 EC sorbents 
at ammonia concentrations of 6 % (MF C l8) and 8 % (C l8 EC and C8 EC), while 
relatively poor recovery was obtained with the C l8 sorbent at all concentrations of 
ammonia Again, as for clenbuterol, it is the Cl 8 EC sorbent, the least polar of the four 
sorbents, which yields the highest recovery of salbutamol (87%)
The results indicate that the C l8 EC sorbent is the most suitable sorbent for the 
simultaneous extraction of clenbuterol and salbutamol, and that an elution solvent of 8% 
NH3 in methanol is an appropriate elution solvent for this combmed extraction
5 3 3 REDUCTION OF MATRIX INTERFERENCE IN FINAL 
EXTRACTS
Determination of clenbuterol and salbutamol at fortification levels lower than 50 ng/g 
proved difficult due to the amount of matnx interference present m the sample extracts 
which affected the radioimmunoassay Where a small aliquot of sample extract can be 
used m the RIA (equivalent to 4 mg of tissue) interference is negligible, but use of larger 
aliquots of extract, which is necessary to achieve low ppb detection capability, requires 
much cleaner extracts The further clean-up was investigated by evaluating the possibility
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of using both organic and aqueous washing solutions m combination with the acetic acid 
and methanol MSPD/IE washing procedure The aqueous washes mcluded a phosphate 
buffer wash (50 mM, pH 6 0) and a water wash, while the organic solvents investigated 
were hexane and acetomtnle Previous work with mixed-mode SPE has shown pH 6 0 to 
be an effective pH for the selective retention of the P-agomsts and elution of interferences 
A phosphate buffer wash was evaluated both before and after the acetic acid wash and as 
a replacement for the acetic acid washing step Hexane and acetomtnle were evaluated as 
possible organic wash solvents All wash steps were applied as 8 ml volumes 
Liver samples, assayed as being free of p-agomst residues, were blended with 2g C l8 EC 
sorbent, combined with lg PRS matenal and the vanous on-column washes were earned 
out The non-specific binding (NSB) values (a measure of the level of interference present 
in the final extract) of the resulting extracts (equivalent to 100 mg sample) were 
determined by radioimmunoassay The details of the six washing procedures and the non­
specific binding value determined for each procedure are shown in Table 5 5 The acetic 
acid=>methanol=>8% NH3 procedure, which gave a NSB value of 2625 cpm, is that used 
for assessment of the four reversed-phase sorbents (5 3 2 above) This high NSB value 
does not permit low ppb determinations The addition of hexane and acetomtnle washes, 
which gave NSB values of 2508 and 2777 cpm, respectively, do not contnbute to any 
further clean-up Lower NSB values (928-1223 cpm) were achieved with the introduction 
of a phosphate buffer wash either before or after the acetic acid washing step, and also as 
an alternative to the acetic acid wash
Liver samples, fortified with clenbuterol and salbutamol at 2 ng/g, were cleaned-up using 
the acetic acid => phosphate buffer => methanol => 8% NH3 washing procedure and 
yielded recovenes of 86% and 70% for clenbuterol and salbutamol, respectively The
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relatively high recovery of both P-agomsts indicate the potential suitability of this washing 
procedure for the analysis of p-agomsts at low ng/g levels
Table 5 5 Evaluation of various wash/elution procedures for MSPD/IE
Wash/elution procedure Non-specific bmdmg (cpm)
AA=>MeOH=>8% NH3 2625
AA=>PB=>MeOH=>8% NH3 928
AA=>HEX=>MeOH=>8% NH3 2508
AA=>ACN=>MeOH=>8% NH3 2777
PB=>MeOH=>8% NH3 1071
PB=>AA=>MeOH=>8%NH3 1008
PB=>H20=>Me0H=>8% NH3 1223
AA = Acetic acid, PB = phosphate buffer, HEX = hexane, ACN = acetonitrile, MeOH = methanol
5.5 CONCLUSION
As an extension of the work on use of mixed-mode SPE for extraction/clean-up of p- 
agomsts from liver (chapter 4), the principles of that approach were combined with the 
MSPD methodology developed for p-agomsts in the laboratory [10-13] The developed 
technique consists of a manual blending of liver with reversed-phase sorbent and further 
mixing of this blend with cation exchange sorbent, pnor to its packing into a synnge barrel 
for a wash/elution sequence This technique gives high recovery of the different types of 
P-agonist and allows for the application of a range of wash steps without substantial loss 
in residue recovery However, the clean-up obtained was insufficient to allow for residue 
determination consistently at the low ppb level It would appear that the mechanism
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involved in retention of the P-agorusts also causes retention of matrix co-extractives which 
act as mterferents in the RIA determination Nonetheless, the developed method 
illustrates a possible new application of MSPD through the use of different sorbent 
chemistries to achieve a single-stage multi-residue procedure
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APPLICATIONS OF SPE TO EXTRACTION AND CLEAN-UP OF 
CLENBUTEROL FROM LIVER WITH DETERMINATION BY RADIO­
IMMUNOASSAY
S Collins, M O’Keeffe, and M R Smyth’
The National Food Centre, Dublin, 'School of Chemical Sciences, Dublin City
University, Dublin, Ireland
INTRODUCTION
The (re)-partitionmg effect of ^ -adrenergic agonists in meat production has been well 
documented (1) The purpose of this study was to develop an efficient extraction 
procedure for clenbuterol from liver samples using Solid Phase Extraction (SPE), with 
determination by radioimmunoassay Following enzymatic digestion of liver in basic 
buffer and centrifugation, the supernatant is purified on a liquid/liquid extraction 
column (2 - 6) Further clean-up is carried out on a silica SPE cartridge and 
clenbuterol is determined in the final extract This method may be suitable as an 
automated procedure
EXPERIMENTAL
Extraction from liver samples
1 25 g of liver was weighed into a 60 ml centrifuge tube Tris buffer containing 
Protease enzyme (Type XXIV) and CaCI2 was added Following homogenisation and 
digestion for one hour at 55°C with repeated vortexing, the digest was centrifuged and 
20 ml of the supernatant was cleaned up on a liquid/liquid extraction column
Liquid/Liquid Extraction Column Clean-up
Clean-up of the primary digest on a Chem Elut column was used to link the extraction 
with a SPE clean-up and concentration step The recoveries of tritiated clenbuterol 
from 20 ml of primary extract under various conditions are shown in Table 1 
Optimum recovery involved a pH adjustment of the primary extract to 12, followed by 
a twenty minute equilibration period with elution of clenbuterol by toluene (60 ml)
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Table 1 Recoveries of tritiated Clenbuterol from primary extract using Chem Elut columns under 
various conditions
Eluant Hexane Toluene To! DCM 
3 1
pH 10 12 10 12 12
Recovery
(%) 41 35 38 80 75
Toi = Toluene
DCM =  Dichloromethane
Silica SPE extraction of Clenbuterol from toluene
Tritiated Clenbuterol was used to develop a method to retain Clenbuterol from toluene 
on a silica cartridge (Sep-Pak) The average recovery of Clenbuterol using elution with 
9 ml ethanol was 88% The complete extraction and clean-up procedure (Figure 1) 
yielded extracts suitable for determination of Clenbuterol by radioimmunoassay (RIA), 
using a kit supplied by Laboratoire d’Hormonologie, Marloie, Belgium
Homogenisation and digestion of 
liver (1 25 g) in TRIS buffer, CaCL2 
and Protease Enzyme XXIV
centrifugation at 2000 rpm/15 mm
s l /
Extraction and clean-up of 
Primary Extract on Chem Elut
elution of Clenbuterol in 60 ml Toluene
\ /
Concentration and clean-up on 
silica cartridge
1
RIA Determination
Figure 1 Flow Chart of Extraction and Clean-up procedure
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RESULTS AND DISCUSSION
The inter-assay and intra-assay variations for the determination of clenbuterol in 
fortified liver are shown in Tables 2 and 3, respectively The inter-assay variation for
Table 2 Inter-assay variation for SPE/RIA determination of clenbuterol in liver
Clenbuterol n Percentage Recovery
added ng/g
mean + SD CV (%)
0 2 5 71 3 ± 7 7 108
0 4 4 56 1 + 6 6 11 7
Table 3 Intra assay variation for SPE/RIA determination of clenbuterol in liver
Clenbuterol n Percentage Recovery
added ng/g
mean ± SD CV (%)
0 2 6 75 3 + 4 7 6 2
0 4 6 54 4 +  9 0 165
determination of clenbuterol in an incurred sample is shown in Table 4 While 
recoveries with this method are relatively low, both the inter-assay and intra-assay 
variations have acceptable coefficients of variation The results in Table 4 indicate that 
the procedure can be successfully applied to incurred liver samples, the concentration 
of clenbuterol in the incurred sample, determined using a standard method, is 0 37 ± 
0 08 ng/g
Table 4 Inter-assay variation for SPE/RIA determination of clenbuterol in incurred liver
Sample n Clenbuterol determined (ng/g)
mean ± SD CV (%)
Incurred 4 0 37 + 0 08 21 5
liver
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Liquid/liquid extraction or liquid/liquid back extraction techniques are not involved, 
avoiding the problem of emulsion formation This, coupled with the lack of any solvent 
evaporation steps, allows for automation of the clean-up step once the primary extract 
has been generated The application of this procedure to other ^-agonist residues, 
such as salbutamol and terbutaline, may result in poor recoveries due to the 
hydrophilic nature of these compounds which reduces their recovery from the 
liquid/liquid extraction column Clean-up steps involving more than one retention 
mechanism, such as mixed phase SPE, may give higher recoveries for multi-residues 
than the procedure outlined here
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Multi-residue Analysis for Beta-agonists in 
Urine and Liver Samples Using Mixed Phase 
Columns With Determination by 
Radioimmunoassay*
Sean Collins, Michael O’Keeffe^
The National Food Centre (Teagasc), Dunstnea Castleknock, Dublin 15, Ireland 
Malcolm R Smyth
School o f  Chemical Sciences Dublin City Universitx Glasnevin, Dublin 7, 
Ireland
A method is described for the extraction of four P-agomsts, 
clenbuterol, salbutamol, mabuterol and terbutahne from 
bovine unne and liver samples using radioimmunoassay (RIA) 
as the method of determination Follow ing enz\ mic digestion of 
the liver samples using protease enz> me the digest is 
centrifuged and the harvested supernatant is saturated with 
sodium chloride and adjusted to pH 11 0 An ethyl 
acetate-propan 2-ol mixture is used to extract the (3-agonists 
from the liver digest The samples of unne and liver extracts 
are adjusted to pH 6 0 and applied to mixed phase (XtrackT) 
columns The column is Hashed with water and methanol and 
the P agonists are eluted with methanol containing 2% 
ammonia After evaporation of the eluting solvent and 
reconstitution in ethanol the p-agonist residues are determined 
by RIA, with standard graphs prepared in residue-free sample 
extract The procedure has been validated for clenbuterol, 
salbutamol, mabuterol and terbutahne The mean recover) of 
the p-agonists from urine and liver is >75% and >85% , 
respectively The detection limit is 0 13 ng ml-1 and 0 46 ng g“ 1 
of clenbuterol in urine and liver, respectivelj The high 
recoveries attained for both types of p-agonists are a result of 
an efficient liquid-liquid extraction step coupled with a 
selective mixed solid-phase extraction procedure
Keywords Beta-agonists, mixed solid phase extraction, residue 
analysis, radioimmunoassay
Introduction
p-Agonists are used therapeutically in the treatment of 
broncho pulmonary disorders m humans and animals It has been established that a number of (3-agonists may exercise a 
repartitioning effect from adipose tissue towards muscle 
tissue, thus, increasing the carcass lean fat ratio in animals 
These metabolic effects have been descnbed when p-agonists 
are administered at dosages of 5-10 times the recommended 
therapeutic dose 1 2 A significant advantage of P-agomsts for growth promotion is that they are orally active which allows 
them to be mixed with animal feed An increase in the carcass 
mass of calves of about 10% occurred when clenbuterol was 
administered orally, without any increase in feed intake 3 The 
use of compounds with hormonal or thyreostatic action was 
prohibited within the EU m 19854 except under veterinary 
prescription Nevertheless, several cases of food poisoning 
were reported m Spain when bovine liver containing high 
levels (>100 ng g_1) of clenbuterol were consumeds
Presented at The Second Internationa) Symposium on Hormone and 
Vetennary Drug Residue Analysis Oud St Jan Bruges Belgium 
May 31-June 3 1994
1 To whom correspondence should be addressed
Salbutamol had been implicated as an alternative 
repartitioning agent to clenbuterol,6 while mabuterol had also 
been used to improve meat-production efficiency in livestock 7
Recent studies have shown that in edible tissues the highest 
concentrations of clenbuterol are found in the liver while an 
even greater accumulation occurs in the tissues of the eye h 9 
Both classes of (3-agomst, the more polar substituted phenol 
type (salbutamol, terbutahne) and the less polar substituted 
aniline type (clenbuterol, mabuterol), have been determined 
in a variety of biological matrices such as plasma unne and 
liver High-performance liquid chromatograph) (HPLC) cou 
pled with ultraviolet, electrochemical or fluorescence detec­
tion has been used to determine clenbuteroluwn and salbu­
tamol 13-17 Immunoassays have been developed for clenbute­
rol18 and salbutamol19-21 and gas chromatography-mass 
spectrometry (GC-MS) has been used for the anal) sis of both 
clenbuterol22 and salbutamol 6
Methods which allow for the simultaneous extraction and 
determination of several (3-agonists from unne and liver have 
been developed using immunoaffinitv chromatography 
(IAC),23 matnx solid-phase dispersion (MSPD)24 and mixed- 
mode solid phase extraction (SPE) 2s-28 Variable recovery of 
(5 agonists of different classes have been reported in previous 
work using mixed-mode solid phase extraction
The present method uses a combination of liquid—liquid 
extraction and mixed mode sohd-phase extraction for the 
extraction of four j3~agonists [clenbuterol (1), salbutamol (2), 
mabuterol (3), terbutahne (4)] (Fig 1) from unne and liver with determination by radioimmunoassay (RIA) The 
recovery of the more polar (3-agomsts from liver is enhanced through the use of a high ionic strength liquid-liquid extrac tion step while still maintaining the recovery of less polar 
|3~agonists The advantage of this method is that high recoveries are attained for all four (3-agonists from unne and 
liver using a relatively simple procedure
Experimental 
Reagents and Equipment
Ethyl acetate ( pesticide’ grade), methanol ( HiPerSolv’) and 
ammonia solution (35%, ‘AnalaR’) were supplied by BDH 
(Poole, Dorset, UK) Propan-2-oI (‘HPLC’ grade) was 
supplied by Aldnch (Dorset UK) and ethanol ( absoluie 
G R ) was obtained from Merck (Darmstadt, Germany) 
Other chemicals used were of AnalaR grade from BDH, or 
equivalent Sue d ’Helix pomatia [containing (3-glucuronidase 
(100000 U ml"1 and sulfatase (1000000 U m l'1)] was supplied by Sepracor (Villeneuve la Garenne, France) 
Protease enzyme, type XXIV (bactenal), was obtained from
2672 Analyst December 1994 Vol 119
Stgma (St Louis, MO, USA) XtrackT mixed mode solid 
phase extraction columns (500 mg sorbent size) were supplied 
bv Technicol (Stockport, UK) The immunoassay kit used for 
the determination of (3-agonists was obtained from Labora 
toire d’Hormonologte (Marloie, Belgium), with antiserum 
which had been raised against salbutamol and had principal 
cross-reactivities of 118% 100% 78% and 29% for 1 2 3 and 
4 Phosphate buffer (0 01 mol l " 1 pH 7 0), containing I g M  
gelatin and 0 1 g M  thimerosal was used for the RIA 
Dextran coated charcoal was prepared by adding 2 g of 
activated charcoal (Sigma) and 0 25 g of dextran T70 
(Pharmacia Uppsala, Sweden) to 500 ml of doublv-distiiled 
water The scintillation cocktail was Cocktail T  (BDH) 
Clenbuterol hydrochloride salbutamol and terbutaline were 
obtained from Sigma Mabutero! was provided as a gift by 
Laboratoire d’Hormonologie
Extraction o f Liver Samples
Liver (2 g) was weighed into a 60 ml centrifuge tube A 10 ml 
aliquot of TRIS buffer (0 2 mol l-!  pH 10) containing 
protease enzyme (0 33 mg ml-1) and CaCU (0 i mol I“ 1) was 
added Following homogenization and digestion for 1 h at 
55 °C with periodic mixing, the digest was centnfuged for 20 
min at 2000 rpm A 5 ml aliquot of the supernatant was 
collected, 1 8 g of sodium chloride was added and the pH was 
adjusted to pH 11 0 A volume of 5 ml of ethvl acetate- 
isopropanol (6 + 4) was added to the liver extract and the 
solution was mixed on a horizontal shaker for 15 min The 
sample was centnfuged (2000 rpm, 15 min) and the organic 
phase (4 ml) was collected This step was repeated and the 
combined organic phase (8 ml) was evaporated at 40 °C under 
a gentle stream of nitrogen
CH3I
N —  C — CH3I IH CH3
2
H H CH3I I I
c  — c  — N — c — CH3I I I !OH H H CH3Cl
3
H H CH3I I _ I
C —  C —  N — C — CH3I I I IOH H H CH3
HO
4
Fig 1 Structures of clenbuterol (1) salbutamol (2) mabuterol (3) 
and terbutaline (4)
Mixed-mode Sohd-phase Extraction
A 6 ml aliquot of phosphate buffer (0 1 mol M  pH 6 0) was 
added to the urine sample and the liver extract and the pH was 
adjusted to 6 0 The XtrackT column was conditioned by the 
addition of 5 ml of methanol, 5 ml of doubly-distilled water 
and 2 ml of phosphate buffer (pH 6 0, 0 1 mol l~ l) The 
sample was applied at a rate of 2 ml mm-1 and the column was 
dried for 10 min by drawing air through the column The 
column was washed with 5 ml of water and 5 ml of methanol 
and was dried for 15 min The (3-agonists were eluted from the 
column using 5 ml of methanol containing 2% ammonia The 
collected eluate was evaporated at 40 °C under a gentle stream 
of nitrogen and resuspended in 2 ml or 5 ml of ethanol for liver 
or urine respectively
Radioimmunoassay
Aliquots (0 2 ml) of liver and urine extracts were added to 
culture tubes 0 2 ml aliquots of control (residue-free) liver or 
unne extracts were added to culture tubes containing a 
clenbuterol standard at 0, 10, 40, 100, 250 and 1000 pg for the 
standard graph, and to culture tubes contatmng 500 and 200 pg 
(liver extract) and 1000 and 400 pg (urine extract) each of 1-4 
The samples the clenbuterol standards and |3-agonist 
recovery standards (in duplicate) were evaporated to dryness 
under a stream of nitrogen and redissolved in 0 5 ml of 
phosphate gelatin buffer (pH 7 0) After vortexing, the1 
culture tubes were incubated at 37 °C for 10 min A 0  1 ml 
aliquot of pHjclenbuterol (7500 cpm) and 0 1 ml of antiserum 
were then added and the culture tubes were incubated at 37 °C 
for a further 15 min and overnight at 4°C A 0 5 ml aliquot ot 
dextran coated charcoal was added and the tubes were 
centnfuged for 10 min at 2000 rpm The supernatants were 
decanted into scintillation vtals and 10 ml of Cocktail T  were 
added The vials were counted for 5 min
Method Validation
Bovine unne and liver samples assayed as being free of 
p-agomst residues were used for fortification studies To unne 
samples (5 ml) 10 and 25 \i\ volumes of an ethanolic solution 
containing 1-4 at 1 ug ml-1 were added to give fortification 
levels of 2 and 5 ppb respectively To liver samples (2 g) 10 
and 25 ul volumes ot an ethanolic solution containing the four 
j5 agonists at 0 4 ug ml-1 were added to give fortification levels 
of 2 and 5 ppb, respectively The fortified liver samples were 
left to equilibrate for 10 mm before extraction
Results and Discussion
The XtrackT columns contain two retention mechanisms 
based on octyl and ben2ene sulfonic acid groups bound to the 
silica particles The cation-exchange properties of the column 
coupled with its hvdrophobic retention charactenstics allow 
for retention of a range of |3-agonists Columns of similar 
chemistry to these (Clean Screen DAU) were used previously 
for |3-agomst determination in unne25 26 and for salbutamol in 
liver 2h This paper contains data for the determination of a 
range ot ^-agonists in unne and liver The optimum pH for the 
retention of (3-agomsts was found to be pH 6 0 and the elution 
of these compounds occurred when methanol containing 2% 
ammonia was applied to the column An important charac 
tenstic of this column is that a pre elution wash with 100% 
methanol is possible which results m cleaner sample extracts a 
methanol wash on a conventional reversed phase (C ^) 
column would elute the analytes together with interferences 
The application of liver extracts, following protein precipi­
tation with HC1 and centnfugation directlv to the SPE column 
was not successful due to the amount of matrix interferences
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still present Studies using li\e r extracts fortified with 
(3H]clenbuterol and pHjsalbutamol vielded recoveries of 
<30% in the elution step from the SPE columns Two 
published liquid-hquid extraction procedures for ^-agonists 
were evaluated, teri butanol + eth)l acetate (3 + I )27 and 
ethyl acetate + isopropanol (6 + 4) -*• the latter solvent 
mixture was chosen because of the higher recoveries achieved 
The effect of the pH and ionic strength of the aqueous liver 
extract on the efficienc\ of the liquid—liquid extraction of 
salbutamol was investigated (Table 1) The saturation of the 
aqueous layer with sodium chloride prior to liquid—liquid 
extraction with ethyl acetate-propan-2-ol resulted in good 
recovery of salbutamol at all pH values Saturation of the 
aqueous layer also resulted in the formation of a well-defined 
interface during the extraction procedure 
An increase in non specific binding (NSB) in the RIA is 
caused bv the sample extracts, particularly liver extracts 
mean NSB figures for the extract free buffer, urine extract in 
buffer and liver extract m buffer are 130 cpm (n = 5), 183 cpm 
(n ~  8) and 672 cpm (n — 9), respectively Good quantitative 
measurement was obtained, therefore, b> preparing the 
standard graph (clenbuterol) for both unne and liver assa>s in 
residue free sample extract To allow for the variation in 
specificity of the antibod\ for the four (3 agonists individual 
standards at an appropriate concentration for each analyte 
were prepared in residue-free sample extracts and assayed 
with the samples 
The inter and intra assa> variations of the method for urine 
and liver are shown in Tables 2-5 Adequate recovery of all 
four |3 agonists is achieved from both urine and liver at 
fortification levels of 2 and 5 ng g_1 (Tables 2 and 4) The 
cross reactivity of the antiserum for terbutaline (29%) deter 
mined the lowest fortification level at which the method could 
be validated for all four p agonists under identical expenmen
tal conditions The method is sensitive to lower levels of 
clenbuterol, salbutamol and mabuterol The intra assavvana 
tions for urine and liver demonstrate good repeatability of the 
method for urine and liver assa\s (Tables 3 and 5)
The results obtained from the anahsis of residue free urine 
and liver samples were used to estimate the detection limit 
The detection limit was 0 13 ng ml“ 1 and 0 46 ng g-1 of 
clenbuterol in urine and liver respectively based on the mean 
response for the control sample extracts plus three times the 
standard deviation
Incurred liver samples with residue concentrations (deter 
mined by alternative methods) of 4 0 3 5 and 8 0 ng g_1 of 
clenbuterol, mabuterol and salbutamol, respectively were 
assayed Good agreement was found for the concentrations of 
clenbuterol (4 3 ng g - 1) and mabuterol (4 7 ng g~ ') deter 
mined b> this method but a considerably lower level of 
salbutamol (1 3 ng g_1) was determined The lower level of 
salbutamol determined probably results from the occurrence
Table 3 Intra assay variation for recovery of clcnbuterol salbutamol 
mabuterol and terbutaline in urine (n = 4)
Recovers (%)
ß Agonist
Concen 
tration/ 
ng m l '1 Range Mean ± SD
Relative
standard
deviation
Clenbuterol 2 73-80 77 ± 3  6 4 6
5 86-89 87 ± 1 3 1 4
Salbutamol 2 5^-68 65 ± 7  3 11 4
5 70-86 77 ± 6  8 8 8
Mabuterol 2 84-91 90 ± 4  6 1
5 87-92 91 ± 2  5 2 8
Terbutaline 2 48-78 69 ± 14 0 20 0
5 85-100 94 ± 7 0 7 4
Table 1 Extraction of salbutamol (5 ppb) from an aqueous solution at 
different pH and sodium chloride levels
ß Agonist 
Salbutamol
Sodium chloride Recovery
pH concentration in 5 ml/g (% )
2 0 0 38
0 8 77
1 8 91
7 0 0 90
0 8 70
1 8 91
10 0 0 74
0 S 70
1 8 88
12 0 0 <¡8
0 8 64
1 8 74
Table 4 Inter assa) variation for recovcrv of clenbuterol salbutamol 
mabuterol and terbutaline in liver (/? = *>)
Recovery (% )
Concen
tration/
Relative
standard
ß Agonist ng g~* Range Mean ± SD deviation
Clenbuterol 2 82-116 92 ± 14 1 15 0
5 70-108 93 ±  14 3 4
Salbutamol 2 80-124 108 ± 1 7  7 In 4
5 99-120 109 ± 8 0 7 3
M abuterol 2 85-116 100 ± 11 2 11 2
5 82-108 94 ±  10 4 11 1
Terbutaline 2 78-119 100± IS 0 15 0
n = 4
5 80-103 96 ± 9 2 9 6
Table 2 Inter assay variation for recover) of clenbuterol salbutamol 
mabuterol and terbutaline in urine (n =  S)
Table 5 Intra assay variation for recovery of clenbuterol salbutamol 
mabuterol and terbutaline in liver (« = 4)
Recovcrv (%) Recover)'(% )
Concen Relative Concen Relative
tration/ standard tration/ standard
ß Agonist ngm l“ 1 Range Mean ±  SD deviation ß Agonist n g g - ' Range Mean ±  SD deviation
Clenbuterol 2 75-92 84 ± 6 0 7 2 Clenbuterol 2 87-99 92 + 5 9 6 45 77-106 92 ±  10 4 11 3 5 81-99 90 ±  8 2 9 0
Salbutamol 2 73-93 85 ±  8 3 9 7 Salbutamol 2 77-117 93 ± 17 0 18 0
5 62-86 76 ±  10 8 14 3 5 89-94 93 ± 2  5 2 7
Mabuterol 2 46-95 79 ±  20 6 26 2 Mabuterol 2 80-93 86 ± 5  6 6 5
5 89-102 98 ± 5  3 5 5 5 83-97 89 ±  6 0 6 7
Terbutaline 2 48-108 81 ±  27 2 33 4 Terbutaline 2 88-123 110 ± 17 0 15 3
5 64-106 82 ±  18 0 21 0 5 62-81 73 ± 8 2 11 2
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Table 6 Comparison of the recovery of terbutaline from urine using XtrackT columns of different size and at different rates of sample 
application (n = 4)
Recovery (% )
Terbutaline
concentration/
Sample
application rate/
XtrackT 
particle size/ Relative standard
ng ml-1 ml min-1 Mean ±  SD deviation
2 0 5 125-210 82 ± 2 7 3 2
0 5 40-50 69 ± 1 4  0 20 0
2 0 40-^0 21* ± 14 4 68 o
5 0 5 125-210 93 ± 7  6 8 1
0 5 40-50 94 ± 7  0 7 4
2 0 40-50 41*± 20 5 50 2
f Within each fortification level mean recovery values with different superscripts are significantly different (p <  0 01)
of salbutamol in liver largelv as a conjugated residue 28 An 
enzymic deconjugation step was introduced into the method, 
0 66 ml sue d’Helix Pomatia (diluted 1 + 10) was added to the 
5 ml of liver digest supernatant which was adjusted to pH 5 0 
and incubated at 37 °C overnight With this modification a 
salbutamol residue concentration of 9 0 ng g " 1 was deter 
mined in the sample
As a result of the hydrophilic character of terbutaline and its 
biphenol like structure (Fig 1), application of terbutaline 
containing urine samples to the SPE columns at a rate in 
excess of 0 5 ml m tn-1 resulted in a significantly reduced 
recovery (determined by analysis of variance) of the com­
pound (Table 6) The effect of the rate of application of the 
samples on recovery was not as pronounced for clenbuterol 
salbutamol or mabuterol XtrackT columns containing the 
same material, but having different particle size, were also 
investigated for their effectiveness in retaining terbutaline 
from urine samples applied at a rate of 0 5 ml min“ 1 It is 
apparent that a larger particle size of the mixed sohd-phase 
extraction column results in higher recoveries of terbutaline 
and lower variability (Table 6), possibly owing to the 
increased surface area of the column
Conclusion
The described method is suitable for the extraction of 
clenbuterol salbutamol mabuterol and terbutaline from 
bovine urine and liver with determination bv RIA Owing to 
the limited cross reactivity of the antibody used in the 
immunoassay step only four (3-agonists could be determined 
however if a detection technique such as GC-M S was used a 
wider range of (3 agonists could be determined An enzymic 
deconjugation step is required to ensure that (3 agonists which 
occur in a conjugated torm (such as salbutamol) are extracted 
and determined This method may be used as a screening 
procedure for (3 agonists giving high recoverv of clenbuterol 
salbutamol mabuterol and terbutaline from urine and liver 
samples
The work reported in this paper was undertaken as part of 
co-ordinated research under the EU FL M R  programme 
(Concerted Action No 8) S C gratefully acknowledges the 
financial assistance Irom the Irish American Partnership 
Scholars Programme
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Rapid analysis of /3-agonists in unne by thermospray tandem 
mass spectrometry
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Abstract
A method is described for the analysis of (3 agonists in unne of cattle The method uses solid-phase extraction 
O P E ), followed by analysis o f the resulting cxtract by flow injection therraospray landem mass spectrometry 
(1SP-M S-M S) Sample prepwration is performed using a mixed-bed S>PC procedure using a sorbent having both 
hydrophobic and ionic properties MS-MS analysis following thermospray ionization, ii> performed m singlc- 
reaction momtonng parent mode In that way lbdopc dilution can be used for quaniitauon of clenbuterol Data arc 
presented on precision and accuracy Tor Ucnbutcrul and rekicd compounds Furthermore, data acquisition was 
pcrfoimed in full-scan neutral loss mode to indicate the iuiUbilitv of flow injection analysis (FIA )-TSP-M S-M S for 
exploratory analysis Detection of 0-agonbb in this mode is based on the presence of the N-te/7 -butyl-/3- 
cthanolamino moiety and in that respect, detection of known as well as unknown compounds having this moiety 
will take place This feature is exemplified by the analysis of samples containing several compounds
1 Introduction
In the EC the use of f i -agonists as growth 
promoting agents in the fattening of animals for 
human consumption is banned Nevertheless 
these compounds are frequently found in the 
unne of cattlc and analysis for the purpose of 
regulatory control is earned out m mast if not 
all, countries Beside*, regulatory control, there 
is a growing interest in methods suitable for 
“real-time” analysis to perform process control 
'Withm the FLA IR (Food-Linked Agro-lndub- 
tnal Research) Concerted Action nr 8 this 
subject was studied extensively and part of the
• Corresponding author
presented work was earned out within the fram e­
work of thu EC project 
Furthermore, an additional analytical problem  
is the use o l slightly modified compounds for 
growth promotion These compounds are usually 
not detected whenever a target-compound ap­
proach is applied 
For regulatory control, the analysis is usually 
earned out using G C -M S in the multiple ion 
detection (M ID ) mode [1,2] Although a very 
effective technique, it has three major draw­
backs the compounds are targeted, so related 
compounds will not be detected, denvatization is 
usually necessary and this may impart unwanted  
selectivity and vanabiUty and, furthermore, the 
procedure typically takes two days to carry out
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W henever the results o f analysis should be 
available on a short turn, as for "real-time” 
analysis, G C -M S methods generally are not very 
suitable In that ease application o f LC -M S-M S  
techniques may offer better performance 
Wc present here a flow injection (F IA )- rSP- 
M b-M S method that may be used in euhcr of 
two ways (a) a method for semi-quanUtative 
target-compound analysis that is suitable for very 
rapid analysis of residues of £ - agonists and (b) a 
method for rapid qualitative group-specific anal­
ysts of nauogram amounts of known as well as 
unknown /3-agonists
2 Experimental
2 1 Materials and instrumentation
AH reagents used were o f analytical gTade 
The absence of £ -agonists in the blank unne 
used for spiking experiments was demonstrated 
using a method based on G C-M S with a limit of 
detection o f 0 2 ng/m l [1J
Clcnbuterol-d6, the analogue of clenbuteroJ 
where six protons at the ten  -butyl moiety are 
substituted with six deutcrons, was used as an 
internal standard, allowing quantitation by iso­
tope dilution
Sample prcpaiation was performed using 
XtrackT columns XRDAF515 (World Wide 
M onitoring, Bristol, PA, USA) containing 500 
mg of a sorbent having ionic and hydrophobic 
properties The clean-up procedure was adapted 
from Lhe procedure published by Montrade et al 
[3] In brief, samples are hydrolyzed using 
glucuronidase/arylsulfatase from Helix pomatia 
at pH 4 8, using acetate buffer for pH adjust­
ment Following hydrolysis, the pH is adjusted 
to 6 0 using 0 1 M  phosphate buffer and the 
extract is applied to a column conditioned with 3 
ml each of methanol» water and 0 1 M  phosphate 
buffer The column is washed with 0 1 W phos­
phate buffer and the analytes are eluted with 
methanol containing 3% concentrated ammo­
nium hydroxide
The analysis is earned out using a Fmmgan 
M AT TSO70 (San Jose, CA , USA) mass spec­
trometer equipped with a thermospray II inter­
face lh e  interface is operated at 200°C block 
temperature and 90°C vaporizer temperature 
The repellcT was at 80 V, no discharge ionization  
was used Argon was used as collision gas at a 
pressure reading of 1 2 mTorr and a collision  
offi>et of - 1 3  eV was applied The earner eluent 
consisted of 30% methanol tn water with an 
overall concentration of 0 05 M  ammonium  
acetate The solvent was» pumped at a flow-rate 
of 1 0 ml/min by a Gilson 305 pump (Villiers-lc- 
Bel, France) equipped with an additional pulse 
damper Aliquots of 5(J ¿¿1 were injected directly 
into the earner eluent by means of a Gilson  
231-401 autosampler
2 2 Data acquisition
To perform semi-quantitative analysis, a pro­
cedure for suigle reaction monitoring (SR M ) in 
parent mode wa* used, momtonng the loss of 
water (Afr 18) and methylpropene (Afr 56) from  
the molecular ions For cimaterol and 
clenbuterol-d* corresponding losses were m oni­
tored (Tabic 1) By applying parent m ode data 
acquisition, the data system will record the 
masses of the precursor ions rather than the 
masses of the product ions In this way the use of  
clenbuterol-dh as an internal standard becom cs  
possible regardless o f the fact that the masb o f  
the product ion monitored is the same as for 
unlabelled clcnbutcrol
Urine samples were spiked with five 0-agom sts 
(cimatcrol, clenbutcrol, terbutahnc, mabuterol 
and salbutamol) at 1, 2 and 5 ng/m l, respective­
ly AliquoLs uf 5 ml of unne each from each  
spiking level were analyzed in triplicate Follow­
ing clean-up, to each extract 15 ng o f  
clenbuterol-dfi, corresponding to 3 ng/m l in  the  
urine, was added as an internal standard The 
extracts were evaporated to dryness and red iv  
solved in 0 50 ml of earner eluent Subsequently 
the extracts were analyzed using FIA —TSP-MS— 
MS m SKM parent mode Aliquots o f  50 /il, 
corresponding to 0 5 ml of unne, were injected  
m duplicate
To perform group-specific qualitative analysis, 
data acquisition is performed m full-scan neutral
J A  van Rhijn et al / J Qtromafogr A 000 (1995) UOO- 000 1
lablò 1
Molecular structure and SRM data for tile investigated analytes
Name R. Ra
HOCH—CH«-
< x . .
*1
■ NH— B1
R* K SRM
Clenbuterol
(CLEN)
c <c h 3), a NHj a 277—»203
Clcnbucci,oWi
(CLEN-d,)
C(CD1),CHJ Cl NHj a 28.1-*203
Mabtiterol
(MAB) C(CH,),
n n h 3 c f , 311 — 237
Terbutaline
(TER)
a c i y , OH H OH
i
226-152
Salbutamol
(SAL)
C(CHj)} c n 2o h OH H
l
240-» 166
Cimaterol
(CIM)
CH(CUj), CN NH, H 220—»160
loss mode The scanning range of the first 
quadrupole is from 200 to 370 u at one scan per 
second Consequently the scan range of the 
second quadrupole is from 126 to 296 u
3. Results and discussion
3 1 Semi-quantitative determination
Fig 1 shows a typical result for the analysis of  
unne samples spiked at 1 ng/m l Table 2 pre­
sents the corresponding quantitative data o f the 
three spiking levels tested From Fig 1 it is dear 
that detection of ail analytes except salbutamol ts 
readily performed at 1 ng/m l level with sufficient 
signal-to-noisc ratio For salbulamol, signal-to- 
noise ratio is low and, although this compound is 
detected, the limit of detection (LO D) is equal 
to 1 ng/m l For the other compounds, based on 
signal-to-noise ratio, a LOD of at least 0 5 ng/ml 
in the urine is achievable Reagent blanks do not 
indicate the presence of any of the analytes
Analysis of the blank unne extract, however, 
seems to indicate the presence of cimateTol and 
clenbutcrol For cimaterol this is most likely 
caused by interfering compounds, becausc all 
unne blanks analyzed during this study show a 
comparable blank offset These interferences 
were not charaaenzcd any further Consequent­
ly, for cimaterol the dean-up has to be improved  
or, alternatively, chromatographic separation of 
the analyte and the interference may be applied 
For clenbuterol, other urine blanks did not show  
an offset, so for this compound it may have been  
incidental contamination However, especially 
for denhuterol the signal is rather small and 
quantitation yields a blank offset of approxi­
mately 0 3 ng/m l 
Quantitation is earned out by using  
clenhuterol-dft as an internal standard Tor clen­
buterol the quantitative results are therefore 
acceptable, especially when taking into account 
that clenbuterol-d6 is only added after clean-up  
so recovery losses arc not corrected For the 
other compounds, quantitative results should he
t. Oo 
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Ï.OO -1 
SO -|
CIM m /ï 220 - >  ISO ° “  »
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> o -
CtEN flV» 2 7 7 -> 2 0 3
i  oo  
'  o -
CLEN-d, . ^ . L L A J ^ k L l  kmfe2ea->203
iOO*
S n
IL1U
MA8
i l
ill. 11 jlA—ILA—A. IL
a.K  U . u , ! !
«tanûarris 10 pg/^ reagent b tenta dank \ nÿml spiked urine srandanls 10 pg/^
urina
Fìg 1 SRM profiles for the FIA-TSP MS-Mb analyse of urme samples spiked at 1 ug/mi with five ^-a^omstfj >
improved Repeatability is again acceptable for 
clenbuterol and perhaps for mabutero! and ter- 
butalinc, but also here improvements have to be 
made H owever, as the use of these compounds 
m the fattening of animals for human consump­
tion is banned within the EC, indication of the 
presence itself is more important than accurate 
quantitative results Improvement of quantita­
tion may be achieved by using isotope-labelled
standards added before clean-up Particularly for 
salbutamol the use of salbutamoi-d6 as an inter­
nal standard could improve quantitation Hie 
results of analysis justify the statement that the 
presented method yields at least semi-quantitd- 
tive information, exccpt for sal hu ta mol 
Together with the clean-up, not including 
hydrolysis, the entire procedure, including cali­
bration, can be performed within two hours for a
Table 2
Results for the analym of clenbutcrol (CLEN) salbutamol (SAL), tnmaterol (CIM), terhutalme (TER) and mabuterol (MAD) m 
spiked urine samples punficd on XtrackT SPE columns
Spike level 
(nfc/ml)
C L W SAL CIM 1ER MAB
Mean
(ng/ml)
CV
( * )
Mean
(ng/ml)
CV
( * )
Mean
(ng/ml)
CV
(%)
Mean
(ttg/ml)
CV
(ft )
Mean
(ng/inl)
CV
(% )
1 0 I 1 15 1 6 28 1 5 25 1 0 21 0 7 21
2 0 2 4 18 4 3 11 2 7 19 1 y 9 1 5 18
5 0 4 4 12 12 2 19 5 9 7 5 6 14 2 9 8
¿c.ôif-*}
(/¡PftOs/
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set of 20 samples» In that respect the method us 
far more rapid than any GC-MS method now 
available
3 2 Qualitative determination
Tandem mass spectrometry may also be used 
for exploratory analysis to detect the possible 
presence of unknown compounds Using neutral 
loss scanning, the loss of 74 u can be monitored, 
corresponding to the loss of water followed by 
the loss of methylpropenc from the molecular 
ion It is assumed that for all N-tert -butyl 
substituted /3-ethanolamines, this fragmentation 
will occur when using alike experimental param­
eters Tor all known compounds this has been 
confirmed in our laboratory
Fig 2 shows the analysis of a 50- t^l aliquot 
corresponding to 0 5 ml of urine, of a unne 
extract spiked prior to clean-up, at 3 ng/ml, with 
several ^-agonists rhc presence of the peak at
4 4 mm indicates the presence of one or more 
compounds that comply with the scanning re­
quirement the loss of 74 u
l*he inset in Fig 2 show* the CID spectrum 
averaged over the peak at 4 4 min This spec­
trum indicates the presence of ^albutamol [M + 
H]+ at m lz 240 and fM + H - H 20 ] + at m lz  
121, terbuiahne [M + H ]+ at m iz  226, clen- 
buterol [M + H]+ at m lz  277/279 and mabuterol 
[M + H]* at m lz  311/313 It is obvious that 
these compounds are readily dctcctcd at this 
concentration level The presence of two frag­
ment ions for salbutamol may be the reason for 
the low sensitivity in the semi-quantitative analy­
sis, bccause there the los>s of 74 u from only one 
ion (m lz  240) is monitored 
To exemplify the detection of possible un­
knowns, a rather artificial experiment was ear­
ned out Recently the abuse of the brominated 
analog of clenbuterol was discovered (4] At that 
time, in our laboratory, GC-MS was used for 
the analysis One of these samples was analyzed 
using ihe presented method Experimental con­
ditions weie the same as in Fig 2 Again an 
aliquot equivalent to 0 5 ml of unne was injected 
while scanning the mass spectrometer for the loss 
of 74 u Fig 3 indicates the presence of com­
Vjg 2 Injection of an extract nf a urine sample spiked ui 3 ng/ml indicating the simultaneous detection of all N-ierf butyl 
substituted compounds present The mass spectrometer was op^ ruled m full *can neutral loss (74 u) mode
fi J A van Rhijn a  at t ]  Chromaiogr A 000 (1991) 000-000
Fig 3 Injcctioo of an extract ot a urine sample crcmphfymg ihc detection of a possible unknown compound The CID spcctrum 
reveals the presence ot bromubutcrol The amount was estimated al 0 7 ng/ml in the urine
pound(s) losing 74 a, and the averaged CID 
spectrum reveals the presence of a compound 
containing two bromine atoms with niono- 
isotopic molecular mas» of 364 > [M + 1I]+ = 365 
This compound was» previously identified as 
bromobutcrol, the brommated analog of clen- 
buterol Using GC-MS, the amount was» esti­
mated al 0 7 ng/ml assumtng a response pd  
mass unit equal to elenbuterol 
From the above examples the possibilities of 
tandem MS for group-specific detection, in this 
case specific for N-tert -butyl substituted £- 
ethanol amines, arc apparent even for low con­
centration levels like 1 ng/ml, although this 
strongly depends on the compound It should be 
emphasized, however, that the loss of 74 u may 
not be an exclusive feature of N-rm -butyl sub­
stituted /3-ethanolamines alone, so mteiference 
may occur Only the analysis of a large number 
of samples from as diverse origin as> possible will 
indicate whether or not the spcuhcity is suffi­
cient Currently this item is under investigation
4 Conclusion
The presented method may be used for rapid 
analysis of several p -agonists m unne m a semi- 
quantitative fasluon at bub-ng/mi levels Analy­
sis is rapid but specificity should be studied more 
extensively Operating the mass spectrometer in 
full-scan neutral loss mode, the possibilities of 
tandem mass spectrometry for group-specific 
detection of structure-related compounds are 
indicated Detection of an unknown as well as 
known compounds at ng/ml level* is demon­
strated
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